

## **LSD use in the United States: Examining user demographics and their evolution from 2015-2019**

Jeremy Weleff, DO<sup>1,2</sup>, Akhil Anand, MD<sup>2,3</sup>, Elizabeth N. Dewey, MS<sup>4,5</sup>, and Brian S. Barnett, MD<sup>2,3</sup>

1. Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA
2. Department of Psychiatry and Psychology, Center for Behavioral Health, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
3. Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, EC-10 Cleveland Clinic, Cleveland, OH, USA
4. Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA
5. Center for Populations Health Research, Cleveland Clinic, Cleveland, OH, USA

### **\*Corresponding author\***

Jeremy Weleff, DO

Yale University School of Medicine / Cleveland Clinic

Neurological Institute, Department of Psychiatry and Psychology

9500 Euclid Ave

Cleveland, Ohio 44195

Phone: 517-803-5675

Fax: 216-636-5860

Email: [weleffj@ccf.org](mailto:weleffj@ccf.org); [jeremy.weleff@yale.edu](mailto:jeremy.weleff@yale.edu)

ORCID Jeremy Weleff: <https://orcid.org/0000-0001-8071-7412>

ORCID Brian Barnett: <https://orcid.org/0000-0002-8963-5701>

Twitter Jeremy Weleff: @JeremyWeleff

Twitter Brian Barnett: @BrianBarnettMD

**Word Count (not including abstract, tables, or references): 3,651**

### **Disclosure Statement**

Dr. Barnett has received stock options from CB Therapeutics as compensation for advisory services and monetary compensation for editorial work for DynaMed Plus (EBSCO Industries, Inc) and consulting services for Cerebral. The other authors report no potential conflicts of interest.

### **Funding**

This work was unfunded.

### **Data availability statement**

Data are publicly available

**Author Contributions:**

**Jeremy Weleff:** Conceptualization, Methodology, Writing- Original Draft Writing, Writing- Review and Editing **Elizabeth Dewey:** Data curation, Methodology, Formal Analysis **Akhil Anand:** Conceptualization, Writing- Review and Editing **Brian Barnett:** Conceptualization, Methodology, Writing- Original Draft Writing, Writing- Review and Editing, Supervision

## LSD use in the United States: Examining user demographics and their evolution from 2015-2019

**Background:** Lysergic acid (LSD) use has risen in the United States (US) in recent years amid increased interest in therapeutic applications of psychedelics. Despite this, contemporary epidemiological investigations of LSD users are few. To expand the literature on this topic, we sought to characterize past-year LSD users in the US and investigate recent demographic evolution within this population.

**Methods:** Using National Survey on Drug Use and Health (NSDUH) data from 2015-2019, we investigated correlates of past-year LSD use and associated changes over the study period.

**Results:** Past-year LSD use increased by 47% from 2015 to 2019 (0.59% to 0.87%). However, among people reporting past-year hallucinogen use disorder there was no significant proportional increase in LSD users. Notable correlates of LSD use on multivariable analysis were: increased LSD access, lower perceived risk of trying LSD, Asian race, low income, fewer children in the home, history of ever selling drugs, being approached by someone selling drugs in the past month, lack of influence of religious beliefs on decision-making, and past-year suicide attempt among people age 18 and older. We found no associations with unemployment, arrest history, past-year psychological distress, or sexually transmitted infections. From 2015 to 2019, the proportion of respondents reporting past-year LSD use who were pregnant, age 26-34, and married increased. Past-year LSD use among lifetime users of methamphetamine also rose.

**Conclusions:** Though still uncommonly used in the US, LSD's societal acceptance may be increasing. Overall, LSD does not appear to contribute significantly to the country's public health problems.

**Keywords:** Lysergic acid, LSD, psychedelics, recreational substance use, epidemiology

### Highlights:

- For the last few years, NSDUH data has shown an increase in LSD use
- Despite this, rates of reported hallucinogen use disorder have not proportionally increased
- Evidence shows increasing societal acceptance for LSD use
- The proportion of respondents reporting past-year LSD use who were pregnant, age 26-34, and married increased
- Past-year LSD use among lifetime users of methamphetamine also rose

## **Introduction**

In 2019, there were estimated to be more than 27 million lifetime lysergic acid diethylamide (LSD) users in the United States (U.S.) (1). Use of LSD in the U.S. has more than doubled since the early 2000s (2) and past-year use remains on an upward trajectory (3). The factors behind this rise are not yet clear, though we speculate that the resurgence of interest in therapeutic applications of psychedelics and associated media may be possible contributors.

Early studies of LSD demonstrated therapeutic promise for its use in alcohol and opioid use disorders, as well as psychological distress associated with cancer (4–6). However, once LSD possession became illegal in the U.S. in 1971, clinical use and human subjects research assessing its therapeutic potential largely ceased. However, research into therapeutic applications of LSD and other psychedelics has returned to the U.S. in recent decades, despite a lack of federal funding to support this work (7). Social acceptability of use of LSD and other psychedelics may be growing, particularly around “wellness” applications of psychedelics. Although most psychedelics remain Schedule I substances in the U.S., a small but growing number of jurisdictions throughout the country have decriminalized or legalized possession of psychedelics. (8).

Despite sustained growth in LSD use, there have been few recent studies of LSD user demographics (2,3,9,10), leaving important gaps in our understanding of who is using LSD and how users might be changing. As a result, we sought to characterize past-year LSD users in the United States from 2015 to 2019 and evaluate whether user demography is evolving.

## **Methods**

### ***Data Description***

The U.S. National Survey on Drug Use and Health (NSDUH) is conducted annually by the Substance Abuse and Mental Health Services Administration (SAMHSA), in all 50 states and the District of Columbia (11). NSDUH personnel administer the survey in person to randomly selected, noninstitutionalized civilians (important excluded populations include people who are imprisoned, hospitalized, or living in nursing homes). The survey inquires about substance use, mental health, other health-related issues, and treatments received for mental health conditions and substance use disorders. It also employs a sample-weighted design that includes weight adjustments for demographics, non-response, and other factors (12).

This study uses pooled data from NSDUH survey years 2015 to 2019 on all respondents (age 12 and older). Although 2020 survey data were available, data collection that year was disrupted due to COVID-19, and NSDUH administrators have advised researchers to avoid comparing 2020 data to those from previous years due to methodological alterations (13). The primary outcome for this study was past-year LSD use, which is an imputed variable in the NSDUH data set. There were no missing data for the outcome.

### ***Statistical Analysis***

Unweighted frequencies for the primary outcome variable are reported, but unweighted frequencies for individual variables are not reported, similar to other publications that utilize NSDUH data. Continuous factors are summarized as weighted medians and interquartile ranges, and comparisons between LSD use groups were evaluated with log-transformed linear regression. Categorical factors are summarized using weighted percentages and 95% confidence

intervals, and comparisons between LSD use groups were evaluated using Rao-Scott chi-square tests.

Univariable associations with LSD use were adjusted for survey year (2015-2019), age group (12-17, 18-25, 26-34, 35-49, 50+), gender (male, female), education (high school but no diploma, high school diploma/GED, some college/no degree, 2-year degree, 4-year degree), employment status (full-time, part-time, unemployed, other), marital status (never been married, married, divorced, widowed), ethnicity/race (White, Black, Asian, Hispanic, other), metropolitan area (small, large, non), religious beliefs (combination of importance and influences decision making), and criminal arrest history (yes/no). Associations were evaluated within each study year, and across study years for consistency. Where the association with LSD use was not consistent across survey years, orthogonal polynomial contrasts were used to determine if a linear trend was present.

Logistic regression was used to calculate adjusted odds ratios for the risk of past-year LSD use. All odds ratios were adjusted for the factors listed above. In addition to evaluating factors individually, three separate multivariable models were constructed: 1) for respondents under the age of 18; 2) for respondents over the age of 18; 3) for respondents of all ages. In the all ages model, questions that were not asked to respondents under the age of 18 or had answers that were nearly universal were recoded to either incorporate ages 12-17 as its own group or combined into the appropriate group (e.g., employment status). The model for respondents over age 18 included questions about mental health that could not be included in the all ages or under age 18 model. Multivariable models were constructed with factors associated with LSD use, after adjusting for

the factors listed above. Models were simplified wherever appropriate to reduce complexity and to address multicollinearity and confounding.

Independent variables in our multivariable logistic regression models consisted primarily of factors previously associated with LSD use. For details about variable selection, please see Appendix A of the supplement.

Survey analysis procedures were used for all analyses due to the complex survey design, utilizing the NSDUH respondent weight, replicate, and variance strata. Since this study utilizes five years of survey data, the respondent weight was divided by five for analyses that included all study years. Significance was assessed at  $p < 0.05$ . Analysis was conducted in SAS 9.4 (SAS Inc., Cary, NC).

### ***Ethics***

This study was approved by the Cleveland Clinic Institutional Review Board.

## **Results**

### ***Demographic Characteristics of LSD Users***

The final unweighted sample size was  $N=282,768$ , and 3,632 respondents reported past-year LSD use (past-year weighted prevalence 0.77%, 95% Confidence Interval: 0.72-0.81%). All investigated respondent factors were significantly associated with past-year LSD use on univariate analysis except for number of religious services attended in the past year and participation in government assistance programs in the current year. Compared to non-LSD

users, past-year LSD users were disproportionately: male (67.9% vs 48.3%), between the ages of 18-25 (56.4% vs 12.3%), White (71.1% vs 62.8%), lesbian, gay, or bisexual (18.0% vs 4.9%), living in a large metropolitan area (59.4% vs 55.9%), never married (85.7% vs 28.1%), without children younger than 18 in the home (92.8% vs 73.3%), unemployed or employed part-time (35.1% vs 17.3% in age 18+), lower income (less than \$20,000/year: 25.4% vs 16.1%), and uninsured (85.4% vs 90.7%). LSD users were also disproportionately likely to strongly disagree that their religious views influenced their decisions (45.7% vs 17.3%), strongly disagree that their religious views were a very important part of their life (43.8% vs 17.5%), report experiencing past-year serious psychological distress: (36.3% vs 11.1%), and report attempting suicide in the past year (3.9% vs 0.54%) (all  $p < 0.001$ ). For further details see Table 1.

**[Table 1 near here]**

All respondents who reported drug use were disproportionately represented among past-year LSD users; aside from tobacco, alcohol, marijuana, and cocaine, respondents who had not used LSD in the past year rarely had lifetime experience with other drugs (<10% non-LSD users reported using each of the other drugs assessed). Prevalence of past-year hallucinogen use disorder was disproportionately higher in past-year LSD users than non-users (6.6% vs 0.06%), as was history of ever using a needle to inject drugs (7.1% vs 1.6%). Past-year LSD users also disproportionately reported that LSD was very easy or fairly easy to obtain (53.0% vs 12.8%). See Supplemental Table 1 for further details.



Past-year LSD users disproportionately reported that there was no risk in: smoking marijuana once or twice a week (65.9% vs 18.5%), trying LSD once or twice (34.9% vs 3.2%), using LSD once or twice a week (12.0% vs 1.4%), trying heroin once or twice (2.3% vs 1.2%), using cocaine once or twice a week (1.3% vs 1.04%), or having 5 or more drinks once or twice a week (5.8% vs 3.1%) (all  $p < 0.001$ ). A notable exception was using heroin once or twice a week, which 0.83% of LSD users reported as no risk compared to 0.91% of non-users ( $p = 0.002$ ). See Supplemental Table 2 for further details.

### ***Demographic changes from 2014-2019***

Past-year LSD use significantly increased by 47% from 2015 to 2019 (0.59% to 0.87%,  $p < 0.0001$ ) (Table 2). Yearly relative increases were higher between 2015-2016 (20.3%) and 2016-2017 (14.1%) but were modest between 2017-2018 (3.7%) and 2018-2019 (3.6%). There were strong within-year associations with past-year LSD use for nearly all respondent factors for each study year,  $p < 0.001$ ; exceptions were metropolitan area (large metro range: 53.2% to 60.9%,  $p = 0.002$  to 0.61) and female pregnancy (range 0.8% to 3%,  $p = 0.03$  to 0.78). These associations remained consistent across the study period with a few notable exceptions. Past-year LSD users were predominantly between the ages of 18-25 in every year, but the proportion of users aged 26-34 increased nearly every year from 16.3% in 2015 to 26.5% in 2019 ( $p < 0.0001$ ). The proportion of past-year LSD users who were married also increased over the study period from 5.7% in 2015 to 10.1% in 2019 ( $p < 0.0001$ ), as did the proportion who reported being pregnant at the time of NSDUH participation (though not necessarily at time of LSD use), which increased from 1.1% in 2015 to 2.1% in 2019 ( $p < 0.0001$ ).

**[Table 2 near here]**

Associations between past-year LSD use with the use of other drugs were consistent across the study period, except for rising past-year LSD use among lifetime users of methamphetamine (22.6% in 2019 vs 14.0% in 2014,  $p=0.04$ ). There was no statistically significant change in the proportion of people with hallucinogen use disorder reporting past-year LSD use ( $p=0.42$ ). For more information see Supplemental table 3.

***Multivariable modelling of risk for past-year LSD use***

In the all ages past-year LSD use multivariable model, factors associated with higher risk of past-year LSD use were: more recent survey year ( $p<0.001$ ), age 12-17 ( $p=0.007$ ), part time employment ( $p<0.001$ ), non-Hispanic Asian race ( $p=0.04$ ), non-influential and unimportant religious beliefs ( $p<0.001$ ), having sold illegal drugs at least once ( $p<0.001$ ), lifetime use of alcohol, marijuana, stimulant, sedatives or any hallucinogen assessed besides LSD ( $p<0.001$ ), having been approached by someone selling illegal drugs in the past month ( $p<0.001$ ), lower perceived risk of trying LSD once or twice ( $p<0.001$ ), and reported easier access to LSD ( $p<0.001$ ).

In the under age 18 multivariable model, factors associated with higher risk of past-year LSD use are: non-influential and unimportant religious beliefs ( $p=0.02$ ), overnight stay in a hospital during the past year ( $p=0.01$ ), lifetime use of tobacco, alcohol, marijuana, stimulant, sedative, or any hallucinogen assessed besides LSD ( $p<0.001$ ), being approached by someone selling illegal drugs in the past month ( $p=0.02$ ), lower perceived risk of trying LSD once or twice ( $p<0.001$ ), and reporting easier access to LSD ( $p<0.001$ ).

In the over age 18 multivariable model, factors associated with higher risk of past-year LSD use were: more recent survey year ( $p=0.001$  for 2017 and 2018,  $p<0.001$  for 2019), part time employment ( $p<0.001$ ), non-Hispanic Asian race ( $p=0.02$ ), non-influential and unimportant religious beliefs ( $p<0.001$ ), having sold illegal drugs at least once ( $p<0.001$ ), past-year suicide attempt ( $p=0.01$ ), lifetime use of marijuana, stimulants, sedatives, or any hallucinogen assessed besides LSD ( $p<0.001$ ), having been approached by someone selling illegal drugs in the past month ( $p<0.001$ ), lower perceived risk of trying LSD once or twice ( $p<0.001$ ), and reported easier access to LSD ( $p<0.001$ ).

Factors associated with decreased risk of past-year LSD use were similar in all models. In the all-age and over-18 models the factors associated with decreased risk are: marriage ( $p<0.001$ ), female gender ( $p<0.001$ ), income more than twice the federal poverty threshold ( $p<0.001$ ), and having children under 18 years old in the home ( $p<0.001$ ). In the all-ages model, older respondents (age  $>18$ ,  $p<0.001$ ) were less likely to try LSD. In the under-18 model, female gender ( $p=0.004$ ) was associated with decreased risk of LSD use. For details of these models see Table 3.

**[Table 3 near here]**

## **Discussion**

This study provides a detailed look at past-year LSD users in the U.S. from 2015 to 2019. Our findings support other recent findings indicating growing LSD use in the United States (2,3), with past-year LSD use increasing by 47% from 0.59% to 0.87% between 2015 and 2019.

Considering that 2019 past-year use prevalence was 65.1% for alcohol, 26.2% tobacco products,

17.5% for marijuana, 3.7% for opioids, 2.0% cocaine, 1.9% tranquilizers, and 1.8% for stimulants (1,14), LSD remains an uncommonly used drug in the United States. Notably, despite recent increases in past-year LSD use there was not a statistically significant increase in the proportion of past-year LSD users among people with lifetime history of hallucinogen use disorder, suggesting that other hallucinogens may be more strongly associated with that diagnosis than LSD.

On multivariable analysis, we found that the people most likely to use LSD in the past year were unmarried, non-Hispanic white or Asian men under the age of 26, with no children in the home, with previous alcohol and other substance use, who are employed part time, earning less than twice the federal poverty threshold, consider their religious views to be unimportant, perceive LSD use to be low risk, and have increased access to LSD. Education level appears unrelated to risk of LSD use, as does urbanicity, enjoyment of risky activities, and sexual identity. Past-year LSD use's lack of association with previous arrest history or past-year sexually transmitted infection (STI), hospitalization, and psychological distress suggests that LSD does not significantly contribute to crime, unsafe sexual practices, or psychiatric problems in the US, though an important exception requiring further exploration was the association between past-year LSD use and past-year suicide attempt in people 18 and older. While we are unaware of reports of suicide attempts in recent clinical trials of LSD (15–18), a large survey of clinicians and researchers treating patients with LSD reported no suicide attempts in research subjects, but 1.2 for every 1,000 patients treated in the community (19). While no conclusion can be made about causality from the data, it is possible that some individuals using LSD may be vulnerable to suicide attempts following use. However, it is also possible that people prone to suicide

attempts or who have recently had one are using LSD to self-treat mental illness, perhaps due to recent favorable media coverage of psychedelic-assisted therapy clinical trials. Unfortunately, information about the temporal relationship between past-year LSD use and suicide attempt, as well as motivators for LSD use, are not collected by the NSDUH, preventing clarification on this topic.

We found that people more likely to use LSD have considerable lifetime drug experience, regardless of age. Notably, the proportion of people who had not used LSD in the past year who believed that using LSD once or twice a week was a “great risk” was more than twice as high as the proportion who believed that using marijuana or having five or more alcoholic drinks once or twice a week was a “great risk.” Only a slightly smaller proportion of non-LSD users believed that using LSD once or twice a week was a “great risk” compared to the proportions believing that using cocaine or heroin twice a week was a “great risk.” These findings suggest that LSD is still considered a “hard core” drug by most of the population, despite users only rarely needing emergency medical treatment following use (20). Interestingly, while perceived risk of LSD was predictably lower in users, most users still considered using LSD once or twice a week to be a “moderate” or “great” risk. This might speak to the sometimes-unpredictable nature of psychedelic experience, which may contribute to LSD’s low addictive potential.

Intriguingly, we found that people whose religious views were not important to their lives and decision-making were at increased risk of past-year LSD use. This was surprising given LSD’s ability to induce mystical experiences (21), which can be transformative in some users (22). This suggests that any enhancement of religious or spiritual beliefs occasioned by LSD may be

transient in nature. This finding contrasts with that of a small study of people from Israel and Australia that showed on univariate analysis that users of LSD, mescaline, and psilocybin, as a group, more highly valued their spirituality than non-users according to scores on the Life Values Inventory (LVI) (23). There are a variety of possible reasons for this difference, including cultural factors, conceptual differences between religious and spiritual beliefs, and the specific questions asked of participants (the LVI asks participants to rank how strongly “Living in harmony with my spiritual beliefs”, “Believing in a higher power” and “Believing that there is something greater than ourselves” guides their behavior, while the NSDUH asks for level of agreement with the statements “Your religious beliefs are a very important part of your life” and “Your religious beliefs influence how you make decisions in your life”), LSD users being combined with users of other psychedelics in the other study, and the fact that our analysis was multivariable and may have adjusted for confounders. The other study also counted individuals who had used small doses of psychedelics as non-users, whereas the NSDUH does not query about dosage.

While we found a decreased risk of LSD use among Black participants on univariate analysis, we found no statistically significant association between being Black and LSD use on multivariate analysis, suggesting confounding factors may explain this previous finding. Previous research found that Black people may be less likely to use LSD and other psychedelics than White people (24), though this study did not control for confounders. Increased risk for lifetime psilocybin use was observed in bisexual participants of a recent study also employing NSDUH data (25), possibly secondary to efforts by bisexual users to employ psilocybin as a means of coping with the effects of minority stress. In contrast, we identified no relationship between past-year LSD

use and sexual identity on multivariable analysis. Regarding another aspect of sexual health, we found no association between past-year LSD use and past-year STIs. Notably, a 2010 study using NSDUH data found that duration of hallucinogen use was positively associated with risk of lifetime STI diagnosis (26).

The differences in correlates between our under age 18 and our 18+ models included increased odds of LSD use among participants under 18 who reported their religious views were not a very important part of their life but still influenced decision-making, overnight stay in a hospital during the past year, and lifetime tobacco use. Unlike in adults, there were no associations with LSD use among participants under 18 who were non-Hispanic Asian race, had higher income, had children in the home, or had religious beliefs that were unimportant and did not influence their decision-making.

Finally, we observed a small number of demographic changes in past-year LSD users from 2015-2019. The proportion of LSD users among lifetime users of all substances analyzed remained unchanged during the study period, except for methamphetamine. Methamphetamine use grew during the study period, and its use is associated with polysubstance use, including growing co-occurring opioid use (27,28) and use among people who use LSD (29). It is unknown whether our finding represents increase simultaneous use of methamphetamine and LSD. Combining LSD with 3,4-Methylenedioxymethamphetamine (MDMA) for synergistic MDMA effects is well known and referred to as “candyflipping” (30,31). However, combining other stimulants appears to be less common (32). In the case of methamphetamine, this may be due to an increased risk of “bad trips” (33) or diminution of LSD’s effects (34). As observed in another

recent study (2), we found that marriage may be a protective factor against LSD use, though it could also be that problematic LSD use or associated drug use produces this finding by contributing to divorce. However, the proportion of married LSD users nearly doubled from 5.7% 2015 to 10.1% in 2019. Though most LSD users remain between the ages of 18 and 25, the proportion of LSD users aged 26-34 grew from 16.3 to 26.5% over the study period. Finally, the proportion of pregnant NSDUH participants reporting past-year LSD use nearly doubled from 1.1% in 2015 to 2.1% in 2019. Though we cannot definitively say this translates into increased use of LSD during pregnancy, this could possibly be the case. Given conflicting evidence on the teratogenic potential of LSD (35), this finding warrants further investigation. Coupled with an overall increase in past-year LSD use during the study period, growth in use among married people, people aged 26-34, and pregnant women, suggests that though LSD remains uncommonly used, societal acceptance in the United States may be growing.

### ***Strengths and Limitations***

The primary strength of this study is its use of data from multiple administrations of a large, rigorously conducted survey employing a nationally representative survey sample. Limitations include the NSDUH's use of retrospective self-report by participants, which could result in underreporting of LSD and other substance use. However, the NSDUH's substance use self-report measures have high concordance with drug testing results (36). NSDUH participation restriction to the civilian non-institutionalized population is another important limitation. While this represents 97% of the US population (13), the NSDUH excludes people living in institutional group quarters such as hospitals, prisons, nursing homes, and addiction treatment centers, who are likely to have important differences in past-year LSD use and demographics.



Further limitations include the fact that the NSDUH does not report number of LSD exposures, doses of LSD used, setting of use, or reasons for LSD use.

## **Conclusions**

Past-year LSD use rose 47% from 2015-2019 in the US, though LSD continues to be used by only a sliver of the US population each year. Use is strongly associated with decreased risk perception around LSD and increased ease of access. Non-users of LSD still consider regular use of LSD to be much riskier than regular use of alcohol or marijuana, though slightly less risky than regular use of cocaine or heroin. With increases in the proportion of past-year LSD users aged 26-34, married, and pregnant, we may be seeing the early stages of increased social acceptance of LSD use. We found no associations on multivariable analysis with unemployment, arrest history, past-year psychological distress, or STIs, suggesting that LSD does not significantly contribute significantly to public health problems in the US.

**Acknowledgements:** This work was supported by a non-monetary scientific collaboration award from the Cleveland Clinic Center for Populations Health Research awarded to Dr. Barnett.

**Funding:** This work was unfunded.

**Disclosure of relationships and activities:** Dr. Barnett has received stock options from CB Therapeutics as compensation for advisory services. He also receives monetary compensation for editorial work for DynaMed Plus (EBSCO Industries, Inc) and consulting services for Cerebral.

## References

1. Center for Behavioral Health Statistics and Quality. Section 1: Illicit Drug Use/Misuse Tables - 1.1 to 1.123 [Internet]. National Survey on Drug Use and Health. 2019 [cited 2022 Jun 17]. Available from: <https://www.samhsa.gov/data/sites/default/files/reports/rpt29394/NSDUHDetailedTabs2019/NSDUHDetTabsSect1pe2019.htm>
2. Killion B, Hai AH, Alsolami A, Vaughn MG, Sehun Oh P, Salas-Wright CP. LSD use in the United States: Trends, correlates, and a typology of us. *Drug Alcohol Depend*. 2021 Jun;223:108715.
3. Yockey RA, Vidourek RA, King KA. Trends in LSD use among US adults: 2015–2018. *Drug Alcohol Depend* [Internet]. 2020;212:108071. Available from: <https://www.sciencedirect.com/science/article/pii/S0376871620302362>
4. Savage C, McCabe OL. Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study. *Arch Gen Psychiatry*. 1973 Jun;28(6):808–14.
5. Krebs TS, Johansen P-O. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. *J Psychopharmacol*. 2012 Jul;26(7):994–1002.
6. Grof S, Goodman LE, Richards WA, Kurland AA. LSD-assisted psychotherapy in patients with terminal cancer. *Int Pharmacopsychiatry*. 1973;8(3):129–44.
7. Barnett B, Parker SE, Weleff J. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020 Title. *Int J Drug Policy*. 2021;
8. Ponienan N. Oregon Becomes First US State To Decriminalize Drug Possession, Begins

- Psilocybin Program [Internet]. Benzinga. 2020 [cited 2022 Jun 24]. Available from: <https://www.benzinga.com/markets/cannabis/20/11/18204455/oregon-becomes-first-us-state-to-decriminalize-drug-possession-begins-psilocybin-program>
9. Yockey A, King K, Vidourek R. “Go Ask Alice, When She’s 10 Feet Tall”: Psychosocial correlates to lifetime LSD use among a national sample of adults. 2019;
  10. Han B, Blanco C, Einstein EB, Compton WM. Mental health conditions and receipt of mental health care by illicit lysergic acid diethylamide (LSD) use status among young adults in the United States. *Addiction*. 2022 Jan;
  11. Substance Abuse and Mental Health Services Administration. 2019 National Survey on Drug Use and Health (NSDUH): Methodological Resource Book, Section 8, Data collection final report. [Internet]. Rockville, MD; 2020. Available from: <https://www.samhsa.gov/data/report/nsduh-2019-data-collection-final-report>
  12. Substance Abuse and Mental Health Services Administration. 2019 National Survey on Drug Use and Health (NSDUH) methodological resource book: Section 2: Sample design report [Internet]. Rockville, MD; 2020. Available from: <https://www.samhsa.gov/data/report/nsduh-2019-sample-design-report>
  13. Substance Abuse and Mental Health Services Administration. 2020 National Survey on Drug Use and Health Public Use File Codebook [Internet]. Rockville, MD; 2021. Available from: <https://www.datafiles.samhsa.gov/sites/default/files/field-uploads-protected/studies/NSDUH-2020/NSDUH-2020-datasets/NSDUH-2020-DS0001/NSDUH-2020-DS0001-info/NSDUH-2020-DS0001-info-codebook.pdf>
  14. Center for Behavioral Health Statistics and Quality. Section 2: Tobacco Product and Alcohol Use Tables - 2.1 to 2.35 [Internet]. National Survey on Drug Use and Health.

- 2019 [cited 2022 Jul 11]. Available from:  
<https://www.samhsa.gov/data/sites/default/files/reports/rpt29394/NSDUHDetailedTabs2019/NSDUHDetTabsSect2pe2019.htm>
15. Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. *J Nerv Ment Dis.* 2014 Jul;202(7):513–20.
  16. Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. *J Psychopharmacol.* 2015 Jan;29(1):57–68.
  17. Holze F, Vizeli P, Müller F, Ley L, Duerig R, Varghese N, et al. Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. *Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol.* 2020 Feb;45(3):462–71.
  18. MindMed. MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders [Internet]. 2022 [cited 2022 Jul 11]. Available from: <https://mindmed.co/news/press-release/mindmed-collaborators-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders/>
  19. Cohen S. Lysergic acid diethylamide: side effects and complications. *J Nerv Ment Dis.* 1960 Jan;130:30–40.
  20. Kopra EI, Ferris JA, Rucker JJ, McClure B, Young AH, Copeland CS, et al. Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD). *J Psychopharmacol.* 2022 Aug;36(8):956–64.
  21. Liechti ME, Dolder PC, Schmid Y. Alterations of consciousness and mystical-type experiences after acute LSD in humans. *Psychopharmacology (Berl).* 2017 May;234(9–

- 10):1499–510.
22. de Rios MD, Grob CS, Baker JR. Hallucinogens and redemption. *J Psychoactive Drugs*. 2002;34(3):239–48.
  23. Lerner M, Lyvers M. Values and beliefs of psychedelic drug users: a cross-cultural study. *J Psychoactive Drugs*. 2006 Jun;38(2):143–7.
  24. Jahn ZW, Lopez J, de la Salle S, Faber S, Williams MT. Racial/ethnic differences in prevalence of hallucinogen use by age cohort: Findings from the 2018 National Survey on Drug Use and Health. *J Psychedelic Stud [Internet]*. 2021;5(2):69–82. Available from: <https://akjournals.com/view/journals/2054/5/2/article-p69.xml>
  25. Yockey A, King K. Use of psilocybin (“mushrooms”) among US adults: 2015–2018. *J Psychedelic Stud [Internet]*. 2021;5(1):17–21. Available from: <https://akjournals.com/view/journals/2054/5/1/article-p17.xml>
  26. Han B, Gfroerer JC, Colliver JD. Associations between duration of illicit drug use and health conditions: results from the 2005-2007 national surveys on drug use and health. *Ann Epidemiol*. 2010 Apr;20(4):289–97.
  27. Jones CM, Compton WM, Mustaquim D. Patterns and Characteristics of Methamphetamine Use Among Adults - United States, 2015-2018. *MMWR Morb Mortal Wkly Rep*. 2020 Mar;69(12):317–23.
  28. Jones CM, Houry D, Han B, Baldwin G, Vivolo-Kantor A, Compton WM. Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction. *Ann N Y Acad Sci*. 2022 Feb;1508(1):3–22.
  29. Palamar JJ, Han BH, Keyes KM. Trends in characteristics of individuals who use methamphetamine in the United States, 2015-2018. *Drug Alcohol Depend*. 2020

- Jun;213:108089.
30. Schechter MD. “Candyflipping”: synergistic discriminative effect of LSD and MDMA. *Eur J Pharmacol.* 1998 Jan;341(2–3):131–4.
  31. Chary M, Yi D, Manini AF. Candyflipping and Other Combinations: Identifying Drug-Drug Combinations from an Online Forum. *Front psychiatry.* 2018;9:135.
  32. Licht CL, Christoffersen M, Okholm M, Damgaard L, Fink-Jensen A, Knudsen GM, et al. Simultaneous polysubstance use among Danish 3,4-methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases. *Hum Psychopharmacol.* 2012 Jul;27(4):352–63.
  33. Smith DE, Rose AJ. The use and abuse of LSD in Haight-Ashbury (observations by the Haight-Ashbury Medical Clinic). *Clin Pediatr (Phila).* 1968 Jun;7(6):317–22.
  34. Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. The pharmacology of lysergic acid diethylamide: a review. *CNS Neurosci Ther.* 2008;14(4):295–314.
  35. Grof S. The Effect of LSD on Chromosomes, Genetic Mutation, Fetal Development and Malignancy. In: *LSD Psychotherapy.* 1st ed. Pomona, CA: Hunter House; 1980. p. 318–47.
  36. Harrison L, Martin S, Enev T, Acknowledgments D. Comparing Drug Testing and Self-Report Of Drug Use Among Youths And Young Adults in the General Population. 2007;

## **TABLES / FIGURES**

### **Table Captions:**

Table 1. Demographic Characteristics by Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.

Table 2. Demographic Characteristics per Study Year by Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.

Table 3. Univariable and Multivariable Adjusted Odds Ratios for the Risk of Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019

**Table 1. Demographic Characteristics by Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

Survey Question	All Respondents (N=282,768)	Past-year LSD use		p-value
		No Past-year Use (N=279,136)	Past-year Use (N=3,632)	
Survey Year				<0.001 <sup>c</sup>
2015	19.7 (19.4, 20.0)	19.7 (19.4, 20.1)	15.2 (13.6, 16.7)	
2016	19.8 (19.5, 20.1)	19.8 (19.6, 20.1)	18.4 (16.2, 20.6)	
2017	20.0 (19.8, 20.3)	20.0 (19.8, 20.3)	21.2 (19.0, 23.3)	
2018	20.2 (19.9, 20.4)	20.1 (19.9, 20.4)	22.2 (19.7, 24.7)	
2019	20.3 (19.9, 20.6)	20.2 (19.9, 20.6)	23.1 (20.9, 25.3)	
Gender Male	48.5 (48.2, 48.8)	48.3 (48.1, 48.6)	67.9 (65.7, 70.0)	<0.001 <sup>c</sup>
Under Age 18 Gender Male	50.9 (50.4, 51.5)	50.8 (50.3, 51.3)	61.5 (56.8, 66.2)	<0.001 <sup>c</sup>
Age 18+ Gender Male	48.3 (47.9, 48.6)	48.1 (47.8, 48.4)	68.7 (66.6, 70.8)	<0.001 <sup>c</sup>
Age Groups				<0.001 <sup>c</sup>
Age: 12-17	9.2 (9.0, 9.3)	9.1 (9.0, 9.3)	11.7 (10.4, 13.0)	
Age: 18-25	12.6 (12.5, 12.8)	12.3 (12.1, 12.5)	56.4 (54.1, 58.8)	
Age: 26-34	14.5 (14.3, 14.7)	14.4 (14.2, 14.7)	22.7 (20.8, 24.6)	
Age: 35-49	22.4 (22.1, 22.7)	22.5 (22.3, 22.8)	6.6 (5.3, 8.0)	
Age: 50+	41.3 (40.8, 41.8)	41.6 (41.1, 42.1)	2.6 (1.2, 4.0)	
Age Groups, Over/Under 18				<0.001 <sup>c</sup>
Under18	9.2 (9.0, 9.3)	9.1 (9.0, 9.3)	11.7 (10.4, 13.0)	
18+ Years	90.8 (90.7, 91.0)	90.9 (90.7, 91.0)	88.3 (87.0, 89.6)	
Race/Hispanicity*				<0.001 <sup>c</sup>
Nonhispanic White	62.8 (62.3, 63.3)	62.8 (62.3, 63.3)	71.1 (68.7, 73.5)	



**Table 1. Demographic Characteristics by Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

Survey Question	All Respondents (N=282,768)	Past-year LSD use		p-value
		No Past-year Use (N=279,136)	Past-year Use (N=3,632)	
Non-Hispanic Black/African American	12.0 (11.7, 12.4)	12.1 (11.7, 12.4)	4.5 (3.6, 5.3)	
Non-Hispanic Native American/Alaskan Native	0.56 (0.51, 0.61)	0.56 (0.51, 0.61)	0.44 (0.22, 0.66)	
Non-Hispanic Native Hawaiian/Pacific Islander	0.38 (0.33, 0.42)	0.38 (0.33, 0.42)	0.37 (0.16, 0.58)	
Non-Hispanic Asian	5.6 (5.4, 5.8)	5.6 (5.4, 5.8)	4.2 (3.1, 5.3)	
Non-Hispanic More Than One Race	1.8 (1.8, 1.9)	1.8 (1.8, 1.9)	3.9 (3.0, 4.7)	
Hispanic	16.8 (16.4, 17.2)	16.8 (16.4, 17.2)	15.6 (13.4, 17.7)	
Sexual Identity, Age 18+ Only				<b>&lt;0.001<sup>c</sup></b>
Heterosexual	94.3 (94.2, 94.5)	94.4 (94.3, 94.6)	81.3 (79.2, 83.3)	
Lesbian Or Gay	1.9 (1.8, 2.0)	1.9 (1.8, 2.0)	4.2 (3.3, 5.0)	
Bisexual	3.1 (3.0, 3.2)	3.0 (2.9, 3.1)	13.8 (12.2, 15.3)	
Don't Know	0.64 (0.58, 0.70)	0.64 (0.58, 0.70)	0.78 (0.28, 1.3)	
Urbanicity				<b>&lt;0.001<sup>c</sup></b>
Large Metro	55.9 (55.4, 56.4)	55.9 (55.4, 56.4)	59.4 (56.9, 61.8)	
Small Metro	29.9 (29.5, 30.4)	29.9 (29.5, 30.4)	29.3 (27.1, 31.5)	
Nonmetro	14.1 (13.8, 14.5)	14.2 (13.8, 14.5)	11.3 (9.7, 12.9)	
Education*				<b>&lt;0.001<sup>c</sup></b>
Under Age 18				<b>&lt;0.001<sup>c</sup></b>
Some HS, No Diploma	98.9 (98.8, 99.0)	99.0 (98.9, 99.1)	94.9 (92.5, 97.4)	
HS Diploma/GED	0.87 (0.78, 0.96)	0.83 (0.74, 0.91)	4.9 (2.5, 7.3)	
Some College, No Degree	0.15 (0.11, 0.20)	0.15 (0.11, 0.19)	0.19 (0.00, 0.57)	
2-Year College Degree	0.00 (0.00, 0.01)	0.00 (0.00, 0.01)	--	

**Table 1. Demographic Characteristics by Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

Survey Question	All Respondents (N=282,768)	Past-year LSD use		p-value
		No Past-year Use (N=279,136)	Past-year Use (N=3,632)	
4-Year College Degree	0.03 (0.01, 0.05)	0.03 (0.01, 0.05)	--	
Age 18+				<0.001 <sup>c</sup>
Some HS, No Diploma	12.7 (12.4, 13.0)	12.7 (12.5, 13.0)	8.3 (7.1, 9.6)	
HS Diploma/GED	24.8 (24.5, 25.1)	24.9 (24.5, 25.2)	23.4 (21.1, 25.8)	
Some College, No Degree	21.6 (21.3, 21.8)	21.4 (21.2, 21.7)	37.1 (34.4, 39.9)	
2-Year College Degree	9.3 (9.1, 9.5)	9.3 (9.1, 9.5)	7.4 (6.2, 8.7)	
4-Year College Degree	31.6 (31.1, 32.1)	31.7 (31.2, 32.1)	23.7 (21.2, 26.1)	
Marital Status*, Age 18+ Only				<0.001 <sup>c</sup>
Married	51.7 (51.3, 52.2)	52.1 (51.6, 52.5)	8.6 (6.5, 10.6)	
Widowed	5.9 (5.7, 6.1)	5.9 (5.8, 6.1)	0.57 (0.00, 1.2)	
Divorced Or Separated	13.8 (13.6, 14.1)	13.9 (13.6, 14.2)	5.1 (3.6, 6.6)	
Never Been Married	28.5 (28.2, 28.9)	28.1 (27.7, 28.4)	85.7 (83.4, 88.1)	
# Children < 18 in Home*				<0.001 <sup>c</sup>
None	73.8 (73.6, 74.1)	73.7 (73.4, 73.9)	92.8 (91.6, 94.1)	
One	10.9 (10.8, 11.0)	10.9 (10.8, 11.1)	4.3 (3.4, 5.2)	
Two	9.7 (9.6, 9.9)	9.8 (9.6, 9.9)	2.3 (1.4, 3.1)	
Three Or More	5.6 (5.4, 5.7)	5.6 (5.5, 5.7)	0.62 (0.22, 1.02)	
Employment Status*				
Under 18				<0.001 <sup>c</sup>
Employed Full Time	4.6 (4.3, 4.8)	4.5 (4.2, 4.8)	8.8 (5.9, 11.8)	
Employed Part Time	24.1 (23.6, 24.7)	24.0 (23.4, 24.6)	33.1 (28.1, 38.0)	
Unemployed	10.8 (10.4, 11.2)	10.7 (10.3, 11.1)	16.3 (12.8, 19.8)	
Other	60.5 (59.8, 61.2)	60.8 (60.1, 61.5)	41.7 (36.4, 47.1)	

**Table 1. Demographic Characteristics by Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

Survey Question	All Respondents (N=282,768)	Past-year LSD use		p-value
		No Past-year Use (N=279,136)	Past-year Use (N=3,632)	
Age 18+				<b>&lt;0.001<sup>c</sup></b>
Employed Full Time	49.4 (49.1, 49.8)	49.4 (49.0, 49.8)	50.6 (47.8, 53.3)	
Employed Part Time	13.1 (12.9, 13.3)	13.0 (12.8, 13.2)	25.4 (23.2, 27.7)	
Unemployed	4.3 (4.2, 4.5)	4.3 (4.1, 4.4)	9.7 (8.3, 11.2)	
Other	33.2 (32.8, 33.5)	33.3 (32.9, 33.7)	14.3 (12.6, 15.9)	
How many employers, age 18+ only / Past-year				<b>&lt;0.001<sup>c</sup></b>
One	74.8 (74.4, 75.1)	75.0 (74.7, 75.4)	48.5 (44.9, 52.1)	
Two	18.3 (18.0, 18.6)	18.1 (17.8, 18.4)	31.6 (29.1, 34.0)	
Three	4.4 (4.3, 4.6)	4.3 (4.2, 4.5)	13.2 (11.4, 15.1)	
Four or more	2.5 (2.4, 2.6)	2.5 (2.4, 2.6)	6.7 (5.3, 8.1)	
Total Family Income*				<b>&lt;0.001<sup>c</sup></b>
Less Than \$20,000	16.2 (15.9, 16.5)	16.1 (15.8, 16.4)	25.4 (23.3, 27.5)	
\$20,00-\$49,999	29.3 (28.9, 29.6)	29.3 (28.9, 29.7)	29.7 (27.5, 31.8)	
\$50,00-\$74,999	15.8 (15.6, 16.1)	15.9 (15.6, 16.1)	14.6 (12.9, 16.4)	
\$75,000 Or More	38.7 (38.1, 39.2)	38.8 (38.2, 39.3)	30.3 (27.6, 33.0)	
# Days skipped work / Past Month, Median [Q1, Q3]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00 [0.00, 0.25]	<b>&lt;0.001<sup>b</sup></b>
Working Cell Phone	97.7 (97.7, 97.8)	97.7 (97.6, 97.8)	98.9 (98.3, 99.5)	<b>0.004<sup>c</sup></b>
Poverty Level (% Of Us Census Poverty Threshold)*				<b>&lt;0.001<sup>c</sup></b>
Living In Poverty	14.8 (14.5, 15.1)	14.7 (14.4, 15.0)	20.5 (19.0, 22.0)	
Income ↑ 2X Fed Pov Thresh	20.0 (19.7, 20.3)	20.0 (19.7, 20.2)	22.0 (20.0, 23.9)	

**Table 1. Demographic Characteristics by Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

Survey Question	All Respondents (N=282,768)	Past-year LSD use		p-value
		No Past-year Use (N=279,136)	Past-year Use (N=3,632)	
Income >2x Fed Pov Thresh	65.2 (64.8, 65.7)	65.3 (64.8, 65.8)	57.6 (55.4, 59.7)	
Participated in 1+ govt assist progr*	18.6 (18.2, 18.9)	18.6 (18.2, 18.9)	17.3 (15.6, 19.0)	0.13 <sup>c</sup>
Covered by any health insurance*	90.6 (90.4, 90.8)	90.7 (90.5, 90.9)	85.4 (83.6, 87.2)	<0.001 <sup>c</sup>
Body Mass Index (BMI) (Age 18+ Only), Median [Q1, Q3]*	27.3 [23.7, 31.7]	27.3 [23.7, 31.7]	23.7 [21.4, 27.4]	<0.001 <sup>b</sup>
Pregnant, Female Only				0.024 <sup>c</sup>
Yes	3.2 (3.1, 3.4)	3.3 (3.1, 3.4)	1.8 (0.66, 3.0)	
No	96.6 (96.5, 96.8)	96.6 (96.5, 96.8)	98.2 (97.0, 99.3)	
Don't Know	0.14 (0.11, 0.16)	0.14 (0.11, 0.16)	0.02 (0.00, 0.06)	
Had sexually transmitted disease / Past Month				<0.001 <sup>c</sup>
Yes	1.9 (1.8, 2.0)	1.9 (1.8, 2.0)	6.9 (5.7, 8.0)	
No	97.9 (97.8, 98.0)	98.0 (97.9, 98.0)	92.7 (91.6, 93.9)	
Don't Know	0.16 (0.14, 0.18)	0.16 (0.14, 0.18)	0.41 (0.11, 0.72)	
# Religious services past 12 months				0.066 <sup>c</sup>
25 Or More	68.1 (67.8, 68.3)	68.0 (67.8, 68.3)	69.8 (67.9, 71.7)	
Less Than 25	31.9 (31.7, 32.2)	32.0 (31.7, 32.2)	30.2 (28.3, 32.1)	
My religious beliefs influence my decisions				<0.001 <sup>c</sup>
Strongly Disagree	17.5 (17.2, 17.7)	17.3 (17.0, 17.5)	45.7 (43.4, 47.9)	
Disagree	15.7 (15.5, 15.9)	15.7 (15.5, 15.9)	23.6 (22.2, 24.9)	
Agree	35.1 (34.9, 35.4)	35.2 (34.9, 35.5)	23.4 (21.6, 25.2)	
Strongly Agree	31.7 (31.4, 31.9)	31.8 (31.6, 32.1)	7.3 (6.0, 8.7)	

**Table 1. Demographic Characteristics by Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

Survey Question	All Respondents (N=282,768)	Past-year LSD use		p-value
		No Past-year Use (N=279,136)	Past-year Use (N=3,632)	
My religious beliefs are very important				<0.001 <sup>c</sup>
Strongly Disagree	17.7 (17.4, 17.9)	17.5 (17.2, 17.7)	43.8 (41.2, 46.3)	
Disagree	13.0 (12.8, 13.1)	12.9 (12.7, 13.1)	22.3 (20.5, 24.1)	
Agree	33.6 (33.3, 33.8)	33.6 (33.3, 33.9)	23.9 (22.1, 25.7)	
Strongly Agree	35.8 (35.5, 36.1)	36.0 (35.7, 36.3)	10.1 (8.6, 11.7)	
Stolen/tried to steal, worth > \$50	1.04 (1.00, 1.08)	0.99 (0.95, 1.03)	7.6 (6.5, 8.7)	<0.001 <sup>c</sup>
Sold illegal drugs	1.5 (1.5, 1.6)	1.4 (1.3, 1.4)	23.2 (21.0, 25.5)	<0.001 <sup>c</sup>
Attacked someone w/intent to seriously hurt them	1.2 (1.2, 1.3)	1.2 (1.1, 1.2)	5.5 (4.5, 6.4)	<0.001 <sup>c</sup>
Ever arrested and booked for breaking the law	15.6 (15.4, 15.9)	15.5 (15.3, 15.7)	33.7 (31.2, 36.2)	<0.001 <sup>c</sup>
# Times arrested and booked past 12 months				<0.001 <sup>c</sup>
None	87.9 (87.5, 88.3)	88.2 (87.8, 88.6)	69.4 (65.0, 73.9)	
Once	9.0 (8.6, 9.4)	8.8 (8.4, 9.1)	22.0 (18.3, 25.6)	
Twice	2.1 (1.9, 2.3)	2.1 (1.9, 2.3)	6.0 (3.9, 8.1)	
Three Or More	0.95 (0.83, 1.07)	0.92 (0.80, 1.05)	2.6 (1.4, 3.9)	
Overnight Stay as Inptnt in Hosp / Past-year	9.5 (9.4, 9.7)	9.6 (9.4, 9.8)	8.1 (6.9, 9.2)	0.018 <sup>c</sup>
Serious psych distress / Past-year	11.3 (11.1, 11.5)	11.1 (10.9, 11.3)	36.3 (33.8, 38.8)	<0.001 <sup>c</sup>
Attempted to kill self / Past-year	0.56 (0.52, 0.60)	0.54 (0.50, 0.58)	3.9 (2.9, 4.9)	<0.001 <sup>c</sup>

Frequencies presented are unweighted counts. Unless otherwise noted, weighted proportions and 95% confidence intervals are reported. \*Imputed or recoded variable reported. P-values: a=linear regression; b=linear regression with log transformation; c=Rao-Scott chi-square test. SAS Survey Procedures used for all analyses.

**Table 2. Demographic Characteristics per Study Year by Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

	2015	2016	2017	2018	2019	2015 vs 2019
<b>Demographic Characteristics</b>	(N=57,146)	(N=56,897)	(N=56,276)	(N=56,313)	(N=56,136)	<i>p</i> -value
<b>Past-year LSD Use</b>	0.59 (0.53, 0.65)	0.71 (0.61, 0.80)	0.81 (0.71, 0.91)	0.84 (0.73, 0.96)	0.87 (0.79, 0.96)	<b>&lt;.0001</b>
<b>Change from Previous Year</b>	--	0.12% (20.3%)	0.1% (14.1%)	0.03% (3.7%)	0.03% (3.6%)	
<b>Age groups</b>						<b>0.01</b>
No LSD Use						
age: 12-17	9.3 (9.0, 9.5)	9.2 (9.0, 9.4)	9.1 (8.9, 9.4)	9.1 (8.8, 9.4)	9.0 (8.7, 9.3)	
age: 18-25	12.7 (12.4, 13.1)	12.5 (12.1, 12.9)	12.2 (11.8, 12.7)	12.1 (11.8, 12.4)	11.9 (11.6, 12.2)	
age: 26-34	14.3 (13.8, 14.8)	14.4 (13.9, 14.8)	14.5 (14.1, 14.9)	14.5 (14.0, 15.0)	14.5 (14.1, 15.0)	
age: 35-49	22.7 (22.1, 23.3)	22.7 (22.1, 23.2)	22.5 (22.0, 23.1)	22.5 (22.1, 22.9)	22.3 (21.8, 22.7)	
age: 50+	41.0 (40.1, 41.9)	41.3 (40.4, 42.1)	41.6 (40.7, 42.5)	41.8 (41.1, 42.5)	42.3 (41.4, 43.1)	
Past-year LSD Use						
age: 12-17	16.1 (12.9, 19.2)	10.7 (7.9, 13.5)	12.5 (10.0, 14.9)	8.4 (6.6, 10.2)	12.0 (9.4, 14.6)	
age: 18-25	63.7 (58.6, 68.7)	61.0 (54.5, 67.4)	57.2 (51.2, 63.2)	52.5 (47.8, 57.2)	51.2 (45.9, 56.5)	
age: 26-34	16.3 (11.6, 20.9)	21.3 (15.0, 27.5)	17.9 (12.5, 23.3)	28.8 (23.0, 34.5)	26.5 (21.5, 31.4)	
age: 35-49	2.5 (0.50, 4.4)	7.1 (3.4, 10.8)	7.4 (4.5, 10.2)	7.9 (4.3, 11.6)	7.1 (4.5, 9.7)	

<b>Table 2. Demographic Characteristics per Study Year by Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.</b>						
	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>2015 vs 2019</b>
<b>Demographic Characteristics</b>	<b>(N=57,146)</b>	<b>(N=56,897)</b>	<b>(N=56,276)</b>	<b>(N=56,313)</b>	<b>(N=56,136)</b>	<b>p-value</b>
age: 50+	1.5 (0.00, 3.7)	0	5.1 (0.96, 9.1)	2.4 (0.00, 5.1)	3.3 (0.60, 5.9)	
<b>Gender male</b>						<b>0.90</b>
No LSD Use	48.3 (47.7, 49.0)	48.3 (47.7, 49.0)	48.4 (47.8, 48.9)	48.3 (47.7, 49.0)	48.3 (47.7, 49.0)	
Past-year LSD Use	67.7 (62.9, 72.5)	69.6 (64.3, 75.0)	65.0 (60.1, 70.0)	68.4 (63.4, 73.5)	68.6 (64.1, 73.2)	
<b>Sexual identity</b>						<b>&lt;.0001</b>
No LSD Use						
Heterosexual, i.e. straight	95.1 (94.8, 95.3)	95.1 (94.7, 95.4)	94.5 (94.2, 94.8)	94.1 (93.8, 94.4)	93.6 (93.3, 93.9)	
Lesbian or Gay	1.8 (1.6, 2.0)	1.8 (1.6, 2.0)	2.0 (1.7, 2.2)	1.9 (1.7, 2.1)	2.0 (1.8, 2.2)	
Bisexual	2.5 (2.4, 2.7)	2.5 (2.2, 2.7)	3.0 (2.8, 3.2)	3.3 (3.1, 3.5)	3.8 (3.6, 4.0)	
Don't know	0.60 (0.49, 0.72)	0.65 (0.53, 0.78)	0.57 (0.44, 0.70)	0.71 (0.58, 0.84)	0.66 (0.54, 0.78)	
Past-year LSD Use						
Heterosexual, i.e. straight	85.1 (80.0, 90.2)	82.2 (77.4, 86.9)	80.7 (77.0, 84.5)	83.3 (80.0, 86.7)	76.5 (70.7, 82.3)	
Lesbian or Gay	3.4 (1.4, 5.3)	6.4 (3.2, 9.7)	2.9 (1.5, 4.2)	3.4 (1.2, 5.5)	4.8 (1.5, 8.1)	
Bisexual	11.2 (6.9, 15.4)	11.0 (7.8, 14.3)	15.1 (11.5, 18.7)	13.0 (10.3, 15.6)	17.3 (12.5, 22.2)	
Don't know	0.34 (0.00, 1.01)	0.38 (0.00, 0.96)	1.3 (0.00, 3.0)	0.33 (0.00, 0.90)	1.3 (0.08, 2.6)	

	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>2015 vs 2019</b>
<b>Demographic Characteristics</b>	<b>(N=57,146)</b>	<b>(N=56,897)</b>	<b>(N=56,276)</b>	<b>(N=56,313)</b>	<b>(N=56,136)</b>	<b>p-value</b>
<b>Race</b>						
						<b>0.04</b>
No LSD Use						
Non-Hispanic White	63.7 (62.7, 64.6)	63.3 (62.4, 64.2)	62.7 (61.8, 63.6)	62.3 (61.4, 63.2)	61.9 (60.9, 62.9)	
Non-Hispanic Black/African American	12.0 (11.4, 12.6)	12.0 (11.4, 12.6)	12.1 (11.4, 12.8)	12.1 (11.5, 12.7)	12.2 (11.4, 12.9)	
Non-Hispanic Asian	5.5 (5.0, 5.9)	5.4 (5.0, 5.8)	5.6 (5.3, 6.0)	5.7 (5.2, 6.1)	5.8 (5.3, 6.3)	
Hispanic	16.3 (15.6, 16.9)	16.5 (15.9, 17.1)	16.8 (16.0, 17.6)	17.1 (16.3, 17.9)	17.2 (16.5, 18.0)	
Other	2.6 (2.4, 2.8)	2.8 (2.6, 3.0)	2.7 (2.5, 3.0)	2.9 (2.6, 3.1)	2.9 (2.7, 3.1)	
Past-year LSD Use						
Non-Hispanic White	71.5 (67.0, 76.0)	71.6 (66.2, 77.1)	72.6 (68.0, 77.1)	70.2 (64.8, 75.6)	69.8 (65.2, 74.5)	
Non-Hispanic Black/African American	5.0 (2.9, 7.2)	3.9 (1.8, 6.0)	4.8 (1.8, 7.9)	4.6 (3.0, 6.2)	4.1 (2.3, 5.8)	
Non-Hispanic Asian	3.4 (1.6, 5.2)	4.1 (1.7, 6.4)	3.4 (1.2, 5.6)	6.1 (3.7, 8.4)	3.8 (1.8, 5.8)	
Hispanic	15.1 (11.2, 19.1)	16.7 (12.1, 21.3)	14.9 (11.6, 18.1)	13.5 (10.3, 16.7)	17.5 (13.6, 21.5)	
Other	4.9 (3.0, 6.9)	3.7 (2.3, 5.2)	4.3 (2.2, 6.3)	5.6 (3.1, 8.1)	4.8 (2.3, 7.2)	
<b>Marital status*</b>						
						<b>0.004</b>
No LSD Use						



**Table 2. Demographic Characteristics per Study Year by Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

	2015	2016	2017	2018	2019	2015 vs 2019
Demographic Characteristics	(N=57,146)	(N=56,897)	(N=56,276)	(N=56,313)	(N=56,136)	<i>p</i> -value
Married	50.4 (49.6, 51.1)	49.4 (48.6, 50.2)	49.6 (48.7, 50.6)	49.4 (48.5, 50.2)	48.8 (48.0, 49.6)	
Widowed	6.0 (5.6, 6.4)	5.6 (5.2, 6.1)	5.3 (4.9, 5.6)	5.5 (5.1, 5.8)	6.0 (5.7, 6.3)	
Divorced or Separated	13.3 (12.8, 13.8)	13.3 (12.8, 13.8)	13.1 (12.6, 13.7)	13.2 (12.7, 13.7)	13.2 (12.6, 13.8)	
Never Been Married	30.3 (29.8, 30.9)	31.6 (30.9, 32.4)	32.0 (31.2, 32.7)	31.9 (31.2, 32.6)	32.0 (31.4, 32.6)	
Past-year LSD Use						
Married	5.7 (3.0, 8.5)	5.6 (2.4, 8.8)	8.2 (5.0, 11.3)	7.9 (4.2, 11.6)	10.1 (5.0, 15.1)	
Widowed	1.03 (0.05, 2.0)	0.16 (0.00, 0.47)	1.2 (0.00, 3.6)	0	0.29 (0.00, 0.87)	
Divorced or Separated	5.3 (1.6, 8.9)	3.3 (1.5, 5.0)	4.5 (1.08, 7.9)	4.0 (1.6, 6.4)	5.8 (3.1, 8.5)	
Never Been Married	88.0 (83.8, 92.1)	91.0 (87.3, 94.6)	86.1 (81.4, 90.8)	88.1 (84.0, 92.2)	83.9 (79.2, 88.5)	
<b>Urbanicity<sup>1</sup></b>						<b>0.94</b>
No LSD Use						
Large Metro	55.9 (54.8, 57.0)	55.8 (54.9, 56.6)	56.2 (55.5, 56.9)	55.7 (54.7, 56.7)	55.9 (54.9, 56.8)	
Small Metro	30.4 (29.4, 31.5)	29.9 (28.9, 30.8)	29.2 (28.5, 30.0)	29.9 (28.8, 30.9)	30.3 (29.4, 31.2)	
Nonmetro	13.7 (13.0, 14.4)	14.3 (13.5, 15.2)	14.5 (13.8, 15.3)	14.4 (13.6, 15.3)	13.8 (13.0, 14.7)	
Past-year LSD Use						

**Table 2. Demographic Characteristics per Study Year by Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

	2015	2016	2017	2018	2019	2015 vs 2019
Demographic Characteristics	(N=57,146)	(N=56,897)	(N=56,276)	(N=56,313)	(N=56,136)	<i>p</i> -value
Large Metro	60.4 (54.9, 66.0)	60.9 (55.2, 66.6)	60.9 (55.7, 66.2)	62.3 (57.4, 67.2)	53.2 (48.1, 58.3)	
Small Metro	29.2 (24.7, 33.7)	28.9 (23.1, 34.7)	27.4 (22.6, 32.2)	28.5 (24.2, 32.7)	32.3 (27.7, 36.9)	
Nonmetro	10.3 (6.9, 13.8)	10.2 (7.3, 13.1)	11.6 (8.8, 14.4)	9.2 (6.5, 12.0)	14.5 (10.3, 18.7)	
<i>p</i> -value	0.11c	0.059c	0.12c	0.002c	0.61c	
<b>Education*</b>						<b>&lt;.0001</b>
No LSD Use						
Some high school, no diploma	22.0 (21.5, 22.5)	20.8 (20.3, 21.3)	20.2 (19.5, 20.9)	20.3 (19.8, 20.8)	19.9 (19.3, 20.4)	
High school diploma/GED	23.1 (22.4, 23.9)	23.0 (22.5, 23.6)	22.2 (21.6, 22.8)	22.7 (22.1, 23.3)	22.2 (21.7, 22.8)	
Some college, no de	19.2 (18.6, 19.7)	19.6 (19.1, 20.0)	19.7 (19.1, 20.2)	19.7 (19.2, 20.2)	19.4 (18.8, 19.9)	
2-year college degr	8.5 (8.1, 8.8)	8.4 (7.9, 8.8)	8.5 (8.1, 8.9)	8.4 (8.0, 8.7)	8.5 (8.1, 8.9)	
4-year college degr	27.2 (26.4, 28.0)	28.2 (27.4, 29.0)	29.4 (28.4, 30.3)	28.9 (28.0, 29.9)	30.1 (29.3, 30.8)	
Past-year LSD Use						
Some high school, no diploma	24.5 (20.2, 28.9)	19.9 (16.0, 23.9)	18.5 (15.4, 21.5)	14.0 (10.9, 17.0)	17.4 (14.0, 20.9)	
High school diploma/GED	21.7 (18.0, 25.4)	22.4 (16.7, 28.1)	22.5 (17.7, 27.3)	17.6 (13.9, 21.2)	22.6 (18.0, 27.1)	
Some college, no de	33.2 (27.9, 38.5)	37.0 (31.0, 43.1)	32.6 (27.3, 37.9)	33.1 (28.6, 37.7)	29.2 (24.5, 33.8)	

**Table 2. Demographic Characteristics per Study Year by Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

	2015	2016	2017	2018	2019	2015 vs 2019
Demographic Characteristics	(N=57,146)	(N=56,897)	(N=56,276)	(N=56,313)	(N=56,136)	<i>p</i> -value
2-year college degr	5.4 (3.0, 7.8)	7.0 (4.1, 9.8)	5.3 (3.4, 7.2)	6.9 (4.2, 9.5)	7.9 (5.4, 10.4)	
4-year college degr	15.1 (11.4, 18.8)	13.6 (9.5, 17.8)	21.2 (16.1, 26.3)	28.5 (23.3, 33.7)	22.9 (18.2, 27.7)	
<b>Employment status*</b>						<b>0.003</b>
No LSD Use						
Employed full time	46.6 (45.9, 47.3)	47.0 (46.3, 47.7)	47.6 (46.9, 48.3)	47.5 (46.7, 48.3)	47.5 (46.7, 48.3)	
Employed part time	13.8 (13.4, 14.2)	13.5 (12.9, 14.1)	13.5 (13.1, 13.9)	13.4 (13.0, 13.8)	13.4 (13.0, 13.9)	
Unemployed	5.0 (4.7, 5.2)	4.8 (4.5, 5.1)	4.6 (4.4, 4.9)	4.3 (4.0, 4.6)	4.2 (4.0, 4.5)	
Other	34.6 (33.8, 35.5)	34.7 (34.0, 35.3)	34.3 (33.5, 35.1)	34.7 (33.9, 35.5)	34.8 (34.0, 35.6)	
Past-year LSD Use						
Employed full time	44.5 (39.2, 49.8)	42.6 (36.5, 48.6)	47.9 (42.3, 53.4)	50.3 (46.1, 54.6)	45.0 (39.5, 50.4)	
Employed part time	27.4 (22.1, 32.7)	29.8 (24.2, 35.3)	22.5 (17.8, 27.2)	25.8 (21.3, 30.2)	26.4 (22.0, 30.8)	
Unemployed	8.0 (5.4, 10.6)	11.8 (8.3, 15.4)	11.5 (7.7, 15.4)	9.6 (6.4, 12.7)	10.7 (7.6, 13.7)	
Other	20.1 (16.0, 24.1)	15.8 (12.1, 19.6)	18.1 (14.6, 21.6)	14.4 (11.4, 17.3)	18.0 (14.0, 22.0)	
<b>Past 12 mos, how many employers, Age 18+ only</b>						<b>0.30</b>
No LSD Use						

**Table 2. Demographic Characteristics per Study Year by Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

	2015	2016	2017	2018	2019	2015 vs 2019
Demographic Characteristics	(N=57,146)	(N=56,897)	(N=56,276)	(N=56,313)	(N=56,136)	<i>p</i> -value
One	75.4 (74.7, 76.1)	74.3 (73.6, 75.0)	74.9 (74.3, 75.6)	75.0 (74.3, 75.6)	74.8 (74.1, 75.6)	
Two	18.1 (17.6, 18.7)	18.5 (17.9, 19.1)	17.7 (17.2, 18.3)	18.4 (17.7, 19.0)	18.3 (17.7, 18.9)	
Three	4.2 (4.0, 4.4)	4.5 (4.3, 4.8)	4.5 (4.2, 4.8)	4.2 (3.9, 4.5)	4.4 (4.1, 4.7)	
Four or more	2.3 (2.1, 2.5)	2.6 (2.4, 2.8)	2.9 (2.6, 3.1)	2.4 (2.2, 2.6)	2.5 (2.2, 2.7)	
Past-year LSD Use						
One	51.7 (45.8, 57.6)	43.0 (36.7, 49.4)	45.6 (39.7, 51.4)	49.7 (43.6, 55.9)	54.1 (47.9, 60.3)	
Two	31.1 (26.3, 36.0)	36.8 (29.4, 44.2)	34.0 (28.6, 39.5)	29.8 (24.3, 35.3)	26.7 (22.0, 31.4)	
Three	11.8 (7.5, 16.1)	13.8 (10.0, 17.5)	13.8 (10.2, 17.3)	13.7 (9.9, 17.4)	11.9 (8.7, 15.1)	
Four or more	5.4 (3.0, 7.8)	6.4 (4.0, 8.8)	6.6 (4.1, 9.2)	6.8 (4.4, 9.2)	7.3 (4.4, 10.3)	
<b>Total family income*</b>						<b>&lt;.0001</b>
No LSD Use						
Less than \$20,000	17.7 (17.1, 18.3)	16.8 (16.1, 17.4)	16.0 (15.3, 16.7)	15.6 (15.0, 16.2)	14.6 (14.1, 15.1)	
\$20,000 - \$49,999	29.8 (29.1, 30.6)	29.8 (29.1, 30.6)	29.3 (28.5, 30.0)	29.2 (28.5, 29.8)	28.3 (27.4, 29.1)	
\$50,000 - \$74,999	16.5 (15.9, 17.0)	15.8 (15.2, 16.4)	15.7 (15.2, 16.2)	15.4 (15.0, 15.9)	15.8 (15.3, 16.3)	

**Table 2. Demographic Characteristics per Study Year by Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

	2015	2016	2017	2018	2019	2015 vs 2019
Demographic Characteristics	(N=57,146)	(N=56,897)	(N=56,276)	(N=56,313)	(N=56,136)	<i>p</i> -value
\$75,000 or More	36.0 (35.1, 36.9)	37.6 (36.6, 38.5)	39.0 (38.1, 40.0)	39.8 (38.9, 40.8)	41.3 (40.3, 42.3)	
Past-year LSD Use						
Less than \$20,000	23.9 (19.2, 28.6)	27.5 (22.3, 32.6)	28.8 (23.6, 33.9)	24.4 (19.6, 29.1)	22.8 (18.3, 27.2)	
\$20,000 - \$49,999	33.3 (28.7, 38.0)	27.7 (23.5, 32.0)	24.8 (21.1, 28.4)	32.7 (28.5, 36.8)	30.4 (25.9, 34.8)	
\$50,000 - \$74,999	12.9 (8.6, 17.1)	17.3 (13.1, 21.4)	16.5 (12.8, 20.2)	11.6 (8.2, 15.0)	14.9 (11.5, 18.3)	
\$75,000 or More	29.9 (24.7, 35.1)	27.6 (22.1, 33.0)	30.0 (25.3, 34.7)	31.4 (26.4, 36.3)	32.0 (26.5, 37.5)	
Poverty level (% of US census poverty threshold)*						<b>&lt;.0001</b>
No LSD Use						
Living in Poverty	15.9 (15.4, 16.4)	15.1 (14.6, 15.7)	14.5 (13.9, 15.1)	14.6 (14.1, 15.1)	13.6 (13.2, 14.1)	
Income ↑ 2X Fed Pov Thresh	20.4 (19.7, 21.1)	20.4 (19.8, 21.0)	20.1 (19.4, 20.7)	19.9 (19.3, 20.4)	19.2 (18.6, 19.8)	
Income > 2X Fed Pov Thresh	63.7 (62.9, 64.6)	64.5 (63.7, 65.3)	65.5 (64.5, 66.5)	65.6 (64.7, 66.4)	67.2 (66.3, 68.1)	
Past-year LSD Use						
Living in Poverty	18.4 (14.6, 22.1)	21.3 (17.3, 25.4)	23.5 (19.0, 28.0)	19.7 (15.8, 23.6)	19.2 (15.2, 23.1)	
Income ↑ 2X Fed Pov Thresh	22.4 (17.7, 27.1)	22.2 (17.0, 27.3)	19.4 (15.7, 23.1)	23.8 (19.3, 28.2)	22.1 (18.1, 26.1)	
Income > 2X Fed Pov Thresh	59.2 (54.0, 64.4)	56.5 (51.9, 61.1)	57.1 (51.3, 62.9)	56.5 (50.4, 62.7)	58.7 (53.4, 64.1)	

**Table 2. Demographic Characteristics per Study Year by Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

	2015	2016	2017	2018	2019	2015 vs 2019
Demographic Characteristics	(N=57,146)	(N=56,897)	(N=56,276)	(N=56,313)	(N=56,136)	<i>p</i> -value
Are you pregnant <sup>2</sup>						<b>0.42</b>
No LSD Use	3.3 (3.0, 3.6)	3.3 (3.0, 3.6)	3.3 (3.0, 3.6)	3.5 (3.2, 3.8)	2.9 (2.6, 3.2)	
Past-year LSD Use	1.1 (0.00, 2.6)	0.80 (0.00, 1.9)	1.6 (0.00, 3.6)	3.0 (0.00, 6.1)	2.1 (0.00, 4.3)	
# Religious services past 12 months <sup>3</sup>						<b>0.01</b>
No LSD Use						
25 or More	67.3 (66.7, 67.9)	67.5 (66.9, 68.0)	68.3 (67.5, 69.1)	68.7 (67.9, 69.4)	68.5 (67.8, 69.2)	
Less than 25	32.7 (32.1, 33.3)	32.5 (32.0, 33.1)	31.7 (30.9, 32.5)	31.3 (30.6, 32.1)	31.5 (30.8, 32.2)	
Past-year LSD Use						
25 or More	66.3 (61.4, 71.2)	69.5 (64.7, 74.2)	68.8 (64.7, 72.9)	71.2 (66.4, 76.0)	71.9 (67.1, 76.8)	
Less than 25	33.7 (28.8, 38.6)	30.5 (25.8, 35.3)	31.2 (27.1, 35.3)	28.8 (24.0, 33.6)	28.1 (23.2, 32.9)	
My religious beliefs influence my decisions						<b>&lt;.0001</b>
No LSD Use						
Strongly Disagree	16.0 (15.5, 16.6)	16.9 (16.4, 17.4)	17.3 (16.7, 17.9)	17.7 (17.4, 18.1)	18.3 (17.7, 18.9)	
Disagree	15.2 (14.6, 15.7)	15.6 (15.2, 16.1)	15.6 (15.1, 16.1)	15.7 (15.2, 16.1)	16.2 (15.8, 16.6)	
Agree	35.8 (35.1, 36.5)	34.9 (34.3, 35.6)	35.1 (34.6, 35.7)	35.6 (34.9, 36.2)	34.7 (34.0, 35.4)	
Strongly Agree	33.0 (32.3, 33.6)	32.5 (31.9, 33.2)	32.0 (31.4, 32.6)	31.0 (30.4, 31.6)	30.8 (30.1, 31.5)	

**Table 2. Demographic Characteristics per Study Year by Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

	2015	2016	2017	2018	2019	2015 vs 2019
Demographic Characteristics	(N=57,146)	(N=56,897)	(N=56,276)	(N=56,313)	(N=56,136)	<i>p</i> -value
Past-year LSD Use						
Strongly Disagree	45.5 (39.5, 51.5)	46.6 (40.3, 52.9)	43.2 (38.1, 48.3)	45.6 (39.7, 51.5)	47.6 (41.4, 53.7)	
Disagree	26.8 (21.5, 32.1)	21.8 (17.5, 26.1)	23.2 (19.8, 26.7)	23.4 (20.0, 26.7)	23.3 (18.8, 27.9)	
Agree	20.8 (16.9, 24.8)	23.9 (18.3, 29.4)	26.5 (21.8, 31.2)	24.6 (18.9, 30.4)	20.7 (16.6, 24.8)	
Strongly Agree	6.9 (3.3, 10.4)	7.8 (4.6, 10.9)	7.1 (4.8, 9.3)	6.5 (3.8, 9.2)	8.4 (5.5, 11.4)	
<b>My religious beliefs are very important</b>						<b>&lt;.0001</b>
No LSD Use						
Strongly Disagree	16.3 (15.8, 16.9)	16.9 (16.4, 17.4)	17.6 (17.0, 18.1)	18.2 (17.7, 18.6)	18.3 (17.8, 18.9)	
Disagree	12.3 (11.9, 12.7)	13.0 (12.6, 13.5)	12.8 (12.4, 13.3)	12.8 (12.3, 13.2)	13.4 (13.0, 13.9)	
Agree	34.1 (33.4, 34.7)	33.2 (32.7, 33.8)	33.3 (32.6, 33.9)	33.8 (33.2, 34.5)	33.7 (33.1, 34.3)	
Strongly Agree	37.3 (36.5, 38.0)	36.8 (36.1, 37.5)	36.4 (35.7, 37.0)	35.2 (34.6, 35.8)	34.5 (33.9, 35.1)	
Past-year LSD Use						
Strongly Disagree	43.5 (38.2, 48.9)	44.1 (37.0, 51.2)	42.2 (37.4, 47.0)	43.5 (37.6, 49.5)	45.2 (39.2, 51.3)	
Disagree	23.2 (18.1, 28.2)	22.6 (17.5, 27.6)	22.0 (17.5, 26.5)	22.1 (18.5, 25.6)	21.8 (18.1, 25.6)	
Agree	25.4 (21.2, 29.6)	21.3 (16.1, 26.4)	25.8 (20.7, 30.8)	25.8 (21.4, 30.2)	21.3 (16.6, 25.9)	

**Table 2. Demographic Characteristics per Study Year by Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

	2015	2016	2017	2018	2019	2015 vs 2019
Demographic Characteristics	(N=57,146)	(N=56,897)	(N=56,276)	(N=56,313)	(N=56,136)	p-value
Strongly Agree	7.9 (4.4, 11.3)	12.1 (7.6, 16.5)	10.0 (7.3, 12.7)	8.6 (5.3, 11.8)	11.7 (7.7, 15.7)	
# Days skipped work past 30 days, median [Q1, Q3]						
No LSD Use	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	<b>&lt;.0001</b>
Past-year LSD Use	0.00 [0.00, 0.26]	0.00 [0.00, 0.00]	0.00 [0.00, 0.31]	0.00 [0.00, 0.51]	0.00 [0.00, 0.05]	
Body mass index (BMI) (Age 18+ only), median [Q1, Q3]*						
No LSD Use	26.6 [23.2, 31.2]	26.7 [23.3, 31.2]	26.6 [23.2, 31.3]	26.9 [23.3, 31.4]	27.0 [23.4, 31.6]	<b>&lt;.0001</b>
Past-year LSD Use	23.8 [21.3, 27.0]	23.9 [21.6, 27.7]	23.5 [20.9, 27.4]	23.4 [21.0, 26.9]	23.7 [21.0, 27.0]	

Frequencies presented are unweighted counts. Weighted proportions and 95% confidence intervals are reported.

\*Imputed or recoded variable.

Reported P-values: a=linear regression; b=linear regression with log transformation; c=Rao-Scott chi-square test.

<sup>1</sup>The association between Past-Year LSD use and Urbanicity was only significant in 2018.

<sup>2</sup>The association between Past-Year LSD use and Pregnancy was only significant in 2016.

<sup>3</sup>There was no association between Past-Year LSD use and the number of religious services attended within any survey year. All other covariates were significantly associated with past-year LSD use within each survey year (p<0.001).

The associations remained stable over time for all covariates except age, marital status, and pregnancy (all p<0.001 for the interaction term with year).

All associations are adjusted for survey year, age, employment, education, race, metropolitan area, and religious importance. SAS Survey Procedures used for all analyses.



**Table 3. Univariable and Multivariable Adjusted Odds Ratios for the Risk of Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

Factor	Univariable AOR	Multivariable AOR		
		All Ages (n = 265,187)	Under Age 18 (n = 59,315)	Age 18+ yrs (n = 198,295)
Survey Year - reference: 2015				
2016	0.98 (0.91, 1.06)	1.13 (0.93, 1.38)	0.68 (0.45, 1.03)	1.22 (0.96, 1.53)
2017	0.99 (0.91, 1.08)	1.33 (1.10, 1.61)*	1.19 (0.87, 1.62)	1.36 (1.10, 1.69)*
2018	1.06 (0.97, 1.16)	1.29 (1.06, 1.58)*	0.77 (0.52, 1.13)	1.38 (1.09, 1.73)*
2019	1.05 (0.97, 1.14)	1.35 (1.15, 1.58)***	1.14 (0.84, 1.56)	1.38 (1.14, 1.66)***
Age Groups - reference: age 18-25				
age: 12-17	0.43 (0.39, 0.48)***	1.39 (1.09, 1.76)*		
age: 26-34	1.04 (0.97, 1.11)	0.40 (0.36, 0.45)***		0.41 (0.36, 0.46)***
age: 35-49	1.80 (1.66, 1.95)***	0.16 (0.12, 0.21)***		0.16 (0.12, 0.22)***
age: 50+	1.73 (1.57, 1.91)***	0.05 (0.03, 0.09)***		0.06 (0.03, 0.10)***
Education - reference: 4-year college degree				
Some HS, no diploma	0.75 (0.69, 0.82)***	1.12 (0.87, 1.44)		1.11 (0.87, 1.41)
HS diploma/GED	0.94 (0.88, 1.00)	1.12 (0.92, 1.36)		1.11 (0.90, 1.36)
Some college, no degree	1.24 (1.16, 1.32)***	1.12 (0.90, 1.38)		1.12 (0.90, 1.40)
2-year college degree	1.18 (1.09, 1.28)***	0.90 (0.69, 1.18)		0.91 (0.69, 1.20)
Employment Status				
Employed part time	1.10 (1.01, 1.19)*	1.32 (1.11, 1.55)*		1.30 (1.09, 1.55)*
Unemployed	1.08 (0.97, 1.20)	1.13 (0.92, 1.39)		1.15 (0.92, 1.44)
Other	0.72 (0.68, 0.76)***	0.96 (0.80, 1.14)		0.92 (0.76, 1.11)
Under age 18	0.16 (0.12, 0.20)***	0.95 (0.60, 1.49)		
Marital Status - reference: Never Been Married				
Married	0.58 (0.54, 0.61)***	0.65 (0.49, 0.87)*		0.65 (0.49, 0.87)*

**Table 3. Univariable and Multivariable Adjusted Odds Ratios for the Risk of Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

Factor	Univariable AOR	Multivariable AOR		
		All Ages (n = 265,187)	Under Age 18 (n = 59,315)	Age 18+ yrs (n = 198,295)
Widowed	0.45 (0.39, 0.53)***	0.89 (0.25, 3.22)		0.95 (0.26, 3.38)
Divorced/Separated	0.92 (0.85, 0.99)*	1.00 (0.72, 1.38)		0.98 (0.71, 1.37)
Gender: Female vs Male	0.74 (0.70, 0.77)***	0.81 (0.73, 0.90)***	0.68 (0.53, 0.89)*	0.77 (0.67, 0.89)***
Sexual Identity - reference: heterosexual, i.e., straight				
Lesbian or Gay	1.22 (0.95, 1.56)	not asked of <18 yrs		0.86 (0.65, 1.15)
Bisexual	2.21 (1.88, 2.61)***			1.21 (0.99, 1.49)
Don't know	1.90 (0.90, 4.01)			2.23 (0.95, 5.23)
Race - reference: Non-Hispanic White				
Other	0.86 (0.76, 0.96)*	1.10 (0.84, 1.44)	1.46 (0.99, 2.15)	1.05 (0.78, 1.43)
Non-Hispanic Black	0.17 (0.15, 0.19)***	0.91 (0.70, 1.19)	0.76 (0.38, 1.50)	0.91 (0.69, 1.20)
Non-Hispanic Asian	0.26 (0.22, 0.31)***	1.40 (1.02, 1.92)*	0.56 (0.17, 1.86)	1.47 (1.06, 2.03)*
Hispanic	0.43 (0.39, 0.46)***	0.96 (0.81, 1.14)	1.04 (0.74, 1.46)	0.96 (0.77, 1.19)
County Metro/Non-Metro Status - reference: Large metro				
Small metro	0.89 (0.84, 0.94)***	0.97 (0.87, 1.09)	0.90 (0.71, 1.15)	0.98 (0.86, 1.11)
Non-metro	0.71 (0.66, 0.76)***	1.14 (0.93, 1.41)	1.11 (0.71, 1.73)	1.13 (0.91, 1.41)
Religious Beliefs - reference: beliefs are important and affect decision-making				
Unimportant, doesn't affect decisions	1.93 (1.85, 2.02)***	1.29 (1.12, 1.49)***	1.30 (0.99, 1.70)	1.28 (1.08, 1.51)*
Unimportant, affects decisions	1.37 (1.26, 1.50)***	1.22 (0.92, 1.61)	1.96 (1.09, 3.53)*	1.17 (0.84, 1.61)
Important, doesn't affect decisions	1.23 (1.13, 1.34)***	1.03 (0.84, 1.25)	0.94 (0.61, 1.46)	1.05 (0.83, 1.34)
Not covered by health insurance	1.15 (0.98, 1.33)	1.02 (0.86, 1.20)	1.43 (0.77, 2.65)	1.00 (0.84, 1.19)
Poverty Level - reference: Living in poverty				
Income ↑ 2X Fed Pov Threshold	0.94 (0.82, 1.08)	0.92 (0.78, 1.09)	1.34 (0.94, 1.92)	0.92 (0.76, 1.10)

**Table 3. Univariable and Multivariable Adjusted Odds Ratios for the Risk of Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

Factor	Univariable AOR	Multivariable AOR		
		All Ages (n = 265,187)	Under Age 18 (n = 59,315)	Age 18+ yrs (n = 198,295)
Income >2X Fed Pov Threshold	0.83 (0.74, 0.92)***	0.72 (0.62, 0.83)***	1.36 (0.97, 1.90)	0.69 (0.59, 0.82)***
Number of children in the home - reference: none				
One child	0.45 (0.36, 0.58)***	0.51 (0.41, 0.64)***	0.36 (0.02, 6.67)	0.52 (0.42, 0.66)***
2 children	0.35 (0.23, 0.53)***	0.44 (0.29, 0.65)***		0.45 (0.30, 0.67)***
3 or more children	0.18 (0.09, 0.34)***	0.23 (0.12, 0.46)***		0.24 (0.12, 0.47)***
Had a STD in last 12 months	2.19 (1.77, 2.71)***	1.15 (0.91, 1.45)	1.27 (0.73, 2.21)	1.14 (0.89, 1.45)
Criminal History				
Sold illegal drugs	8.02 (6.99, 9.20)***	1.68 (1.44, 1.96)***	0.94 (0.68, 1.29)	1.79 (1.50, 2.12)***
Ever Been Arrested	4.89 (4.66, 5.13)***	1.08 (0.91, 1.27)	1.39 (1.00, 1.94)	1.07 (0.89, 1.27)
Mental Health in the past year				
Inpatient overnight stay	1.45 (1.21, 1.74)***	1.18 (0.97, 1.44)	1.55 (1.13, 2.12)*	0.92 (0.73, 1.16)
Serious psych distress	2.00 (1.78, 2.26)	not asked of <18 yrs		1.04 (0.90, 1.20)
Attempted to kill self	2.88 (2.12, 3.93)	not asked of <18 yrs		1.65 (1.11, 2.47)*
Lifetime Drug Use				
Tobacco use	11.20 (9.34, 13.43)***	1.23 (0.98, 1.55)	2.25 (1.48, 3.42)***	0.99 (0.77, 1.26)
Alcohol use	22.42 (15.79, 31.83)***	1.83 (1.25, 2.69)*	1.92 (1.14, 3.23)*	1.51 (0.84, 2.72)
Marijuana use	61.39 (42.37, 88.97)***	7.75 (5.12, 11.73)***	7.26 (4.21, 12.51)***	7.79 (4.61, 13.17)***
Any stimulant use	14.21 (12.26, 16.46)***	2.02 (1.74, 2.35)***	2.29 (1.72, 3.07)***	2.03 (1.70, 2.41)***
Any sedative use	7.15 (6.28, 8.13)***	1.50 (1.31, 1.71)***	2.12 (1.60, 2.80)***	1.41 (1.24, 1.61)***
Any hallucinogen use	21.76 (18.67, 25.36)***	4.36 (3.65, 5.20)***	4.87 (3.81, 6.23)***	4.27 (3.45, 5.27)***
Offered drugs to buy, past mon	4.55 (4.13, 5.02)***	1.33 (1.17, 1.52)***	1.36 (1.06, 1.76)*	1.34 (1.16, 1.55)***
Difficulty of getting LSD - reference: Probably impossible/don't know				

**Table 3. Univariable and Multivariable Adjusted Odds Ratios for the Risk of Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

Factor	Univariable AOR	Multivariable AOR		
		All Ages (n = 265,187)	Under Age 18 (n = 59,315)	Age 18+ yrs (n = 198,295)
Very difficult	5.20 (3.65, 7.41)***	2.64 (1.84, 3.78)***	3.82 (1.93, 7.54)***	2.59 (1.76, 3.83)***
Fairly difficult	13.13 (9.33, 18.48)***	4.23 (3.04, 5.89)***	4.80 (2.80, 8.22)***	4.26 (2.94, 6.17)***
Fairly easy	28.47 (19.59, 41.39)***	7.21 (4.95, 10.50)***	7.43 (3.80, 14.50)***	7.29 (4.84, 10.99)***
Very easy	42.91 (28.75, 64.04)***	9.63 (6.26, 14.83)***	11.14 (5.28, 23.47)***	9.30 (5.80, 14.93)***
<b>Risk attitudes</b>				
Risk of trying LSD once or twice - reference: Great risk				
No risk	39.99 (33.08, 48.34)***	11.43 (9.37, 13.93)***	6.68 (4.46, 10.00)***	12.86 (10.12, 16.35)**
Slight risk	15.54 (12.86, 18.77)***	5.70 (4.56, 7.13)***	3.44 (2.31, 5.12)***	6.35 (4.84, 8.33)***
Moderate risk	3.90 (3.17, 4.79)***	2.34 (1.89, 2.91)***	1.84 (1.31, 2.57)***	2.49 (1.91, 3.26)***
Get a kick out of doing dangerous things - reference: Never				
Seldom	2.38 (1.99, 2.86)***	0.95 (0.78, 1.16)	0.93 (0.59, 1.46)	0.93 (0.75, 1.16)
Sometimes	5.23 (4.44, 6.15)***	1.21 (0.95, 1.54)	0.62 (0.38, 1.02)	1.26 (0.97, 1.63)
Always	8.27 (6.68, 10.24)***	1.24 (0.89, 1.71)	0.76 (0.43, 1.33)	1.28 (0.88, 1.86)
Like to test yourself by doing risky things - reference: Never				
Seldom	2.29 (1.96, 2.67)***	0.98 (0.83, 1.16)	0.88 (0.56, 1.39)	1.00 (0.83, 1.21)
Sometimes	4.24 (3.69, 4.87)***	0.99 (0.81, 1.22)	0.85 (0.52, 1.39)	1.01 (0.81, 1.27)
Always	6.26 (5.34, 7.35)***	0.87 (0.69, 1.11)	0.99 (0.63, 1.56)	0.82 (0.60, 1.11)

Univariable adjusted odds ratios (AOR) were adjusted for survey year, age groups, gender, race, employment status, marital status, education, religious beliefs, criminal arrest, and county metro area.

SAS survey procedures were used for all analysis to adjust for the complex survey design. Any stimulant use includes the use of cocaine, “crack”, methamphetamines, and other stimulants.

Any sedative use includes the use of pain relievers, tranquilizers, heroin, and other sedatives.

**Table 3. Univariable and Multivariable Adjusted Odds Ratios for the Risk of Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

Factor	Univariable AOR	Multivariable AOR		
		All Ages (n = 265,187)	Under Age 18 (n = 59,315)	Age 18+ yrs (n = 198,295)
Any hallucinogen use includes the use of PCP, ecstasy, ketamine, inhalants, peyote, mescaline, psilocybin, and hallucinogen dependency. *p<0.05, **p<0.01, ***p<0.001.				

## **Supplement**

### **“LSD use in the United States: Examining user demographics and their evolution from**

### **2015-2019”**

#### **Appendix A: Statistical analysis details**

Respondents under the age of 18 were not asked survey questions in areas of mental health (ex. attempted suicide) and certain demographics (ex. sexual identity). Additionally, some survey questions were answered overwhelmingly with a single choice in that age group: married status (99% never been married), education (99% some high school but no diploma), employment status (70% unemployed or other), and number of children present in the household (either 0 or 1 only). Analyses on survey questions restricted by age (over/under age 18) were appropriately stratified.

Regarding variable selection for our analyses, we largely selected variables that had previously been associated with LSD use including: year of survey administration (Killion et al. 2021; R. A. Yockey, Vidourek, and King 2020), age (Killion et al. 2021), education level (Killion et al. 2021), marital status (Killion et al. 2021), gender (Killion et al. 2021; A. Yockey, King, and Vidourek 2019), income (Killion et al. 2021), urbanicity (Killion et al. 2021; A. Yockey, King, and Vidourek 2019), race/ethnicity (Killion et al. 2021; A. Yockey, King, and Vidourek 2019), past year psychological distress (Killion et al. 2021), use of other psychoactive drugs (Killion et al. 2021; A. Yockey, King, and Vidourek 2019), previous arrests (Killion et al. 2021), risk taking behavior (A. Yockey, King, and Vidourek 2019), risk perception of LSD and other drugs (R. A. Yockey, Vidourek, and King 2020), sexually transmitted infections (STIs) (Folch et al. 2015), and history of hallucinogen abuse or dependence (Ross and Bogenschutz 2017). Based on evidence that LSD use among bisexual people may be increasing (R. A. Yockey, Vidourek, and

King 2020), we included bisexual and lesbian/gay sexual identity in the models. Since mystical experiences sometimes occur in LSD users (Liechti, Dolder, and Schmid 2017), we also incorporated questions about importance of religious beliefs in the lives of survey participants. All religious factors (religious importance, religion affects decision-making, and number of religious services attended) were highly correlated, so a new variable was created that combined importance and decision-making to create a new four-level factor: religion is important, and influences my decisions, religion is important, but doesn't influence my decisions, religion is not important, but influences my decisions, religion is not important, and doesn't influence my decisions. This new factor was used as a representative of the respondent's religious history.

Given the previously mentioned association between LSD use and risk-taking behavior, we incorporated two additional risk-taking variables: selling illegal drugs at least once and ever using a needle to inject drugs. LSD use has previously been associated with suicidal ideation (Han et al. 2022), so we included a past-year suicide attempt variable (except for those under 18 or in the all-ages model because respondents under 18 were not asked this question). Based on LSD use's correlation with past arrest history, we also evaluated two related variables: ever having stolen anything worth more than \$50 and ever having attacked anyone with intent to seriously hurt them. Access to psychoactive substances is associated with use (Ambrose, Cowan, and Rosenman 2021; MacNabb et al. 2022), so we incorporated variables on reported difficulty accessing LSD and whether the respondent had been approached by someone selling drugs in the previous year. Insurance status was included in the model since it is associated with some types of substance use (Tardelli et al. 2019), though we are unaware of investigations into its relationship with LSD use. Since substance use is associated with medical hospitalizations (Wu,

Zhu, and Ghitza 2018), we incorporated a variable on past-year hospitalization. Because of LSD's association with income level, we incorporated variables for current employment status, number of employers in the past year, and participation in government assistance programs in the current year (a variable combining participation in the Supplemental Security Income or "food stamps" program or receipt of either cash assistance or non-cash governmental assistance), as well as if the respondent reported living in poverty.

Working cell phone access is known to be low in some groups who use drugs (Ozga et al. 2022), but has not been explored with LSD use, so this variable was added. Finally, since parenthood is associated with decreased substance use (Fergusson, Boden, and John Horwood 2012), but also has not been investigated with LSD use, variables on the number of children under 18 years of age in the home and current pregnancy were incorporated into the models.

Factors were evaluated for collinearity, confounding, and model stability. Needle use was excluded from multivariable modeling due to low incidence. The number of employers could not be included in multivariable models, due to confounding with employment. Participation in government assistance and having a working cell phone were both not significantly associated with LSD use and wasn't included in multivariable analysis. Due to strong correlations among all criminal variables, past arrest history was used in multivariable models as a representative factor for criminal history. Pregnancy was excluded from multivariable modeling because it was asked of female respondents only.



## Appendix B: Supplemental Tables

<b>Supplemental Table 1. Drug Use Characteristics by Past Year LSD Use from NSDUH Survey Respondents from 2015-2019.</b>				
<b>Survey Question</b>	<b>Overall</b>	<b>LSD Use within the past year</b>		
		<b>No Past Year Use</b>	<b>Past Year Use</b>	<b>p-value</b>
<b>about Drug Use</b>	<b>(N=282,768)</b>	<b>(N=279,136)</b>	<b>(N=3,632)</b>	
Tobacco / Ever	62.4 (62.0, 62.7)	62.1 (61.8, 62.4)	93.4 (92.4, 94.4)	<0.001 <sup>c</sup>
Tobacco / Past Month	22.5 (22.2, 22.8)	22.2 (21.9, 22.5)	62.4 (60.4, 64.4)	<0.001 <sup>c</sup>
Tobacco / Past Year	27.7 (27.3, 28.0)	27.3 (27.0, 27.6)	77.0 (74.8, 79.1)	<0.001 <sup>c</sup>
Alcohol / Ever	80.6 (80.4, 80.9)	80.5 (80.2, 80.7)	98.4 (97.9, 99.0)	<0.001 <sup>c</sup>
Marijuana / Ever	44.9 (44.6, 45.3)	44.5 (44.2, 44.9)	98.3 (97.7, 98.9)	<0.001 <sup>c</sup>
Cocaine / Ever	14.7 (14.5, 15.0)	14.4 (14.1, 14.6)	62.3 (60.2, 64.4)	<0.001 <sup>c</sup>
"Crack" / Ever	3.4 (3.3, 3.5)	3.3 (3.2, 3.5)	11.3 (9.7, 13.0)	<0.001 <sup>c</sup>
Heroin / Ever	1.9 (1.8, 2.0)	1.9 (1.8, 1.9)	12.0 (10.7, 13.3)	<0.001 <sup>c</sup>
PCP / Ever	2.2 (2.1, 2.3)	2.2 (2.1, 2.3)	6.4 (5.3, 7.5)	<0.001 <sup>c</sup>
Ecstasy / Ever	7.1 (6.9, 7.2)	6.6 (6.5, 6.8)	67.5 (65.3, 69.7)	<0.001 <sup>c</sup>
Ketamine / Ever	1.3 (1.2, 1.3)	1.1 (1.07, 1.2)	21.5 (19.7, 23.2)	<0.001 <sup>c</sup>
Inhalants / Ever	9.2 (9.0, 9.4)	9.0 (8.8, 9.1)	40.5 (38.1, 43.0)	<0.001 <sup>c</sup>
Methamphetamine / Ever	5.5 (5.4, 5.7)	5.4 (5.3, 5.6)	20.3 (18.0, 22.5)	<0.001 <sup>c</sup>
Pain Relievers / Ever Misused	9.8 (9.6, 10.0)	9.5 (9.4, 9.7)	47.8 (45.4, 50.1)	<0.001 <sup>c</sup>
Stimulants / Ever Misused	4.1 (4.0, 4.2)	3.7 (3.7, 3.8)	46.7 (44.3, 49.1)	<0.001 <sup>c</sup>
Tranquilizers / Ever Misused	4.3 (4.1, 4.4)	4.0 (3.9, 4.1)	38.2 (36.0, 40.4)	<0.001 <sup>c</sup>
Sedative / Ever Misused	2.2 (2.1, 2.3)	2.2 (2.1, 2.2)	12.9 (11.5, 14.4)	<0.001 <sup>c</sup>

**Supplemental Table 1. Drug Use Characteristics by Past Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

Survey Question	Overall	LSD Use within the past year		
		No Past Year Use	Past Year Use	p-value
<b>about Drug Use</b>	<b>(N=282,768)</b>	<b>(N=279,136)</b>	<b>(N=3,632)</b>	
Peyote / Ever	2.1 (2.0, 2.2)	2.1 (2.0, 2.2)	7.4 (6.1, 8.7)	<0.001 <sup>c</sup>
Mescaline / Ever	2.9 (2.8, 3.0)	2.8 (2.7, 2.9)	10.0 (8.7, 11.3)	<0.001 <sup>c</sup>
Psilocybin (mushrooms) / Ever	8.8 (8.6, 9.0)	8.4 (8.2, 8.6)	68.8 (66.5, 71.2)	<0.001 <sup>c</sup>
Hallucinogen Dependence or Abuse / Past Year	0.11 (0.10, 0.13)	0.06 (0.05, 0.07)	6.6 (5.4, 7.9)	<0.001 <sup>c</sup>
Needle Use / Ever	1.7 (1.6, 1.7)	1.6 (1.6, 1.7)	7.1 (6.0, 8.3)	<0.001 <sup>c</sup>
How did you get the needle last time, <i>Needle users only</i>				0.07 <sup>c</sup>
Bought/stole/given from pharm, needle exch, lab, store	57.9 (55.7, 60.1)	57.5 (55.2, 59.9)	68.1 (58.7, 77.5)	
Bought/stole/given from friend, relative, work, home	24.1 (22.5, 25.7)	24.3 (22.6, 26.0)	17.4 (9.0, 25.7)	
included with drugs	0.88 (0.47, 1.3)	0.91 (0.48, 1.3)	0.09 (0.00, 0.26)	
Acquired on street, found in trash can, shared needle	8.7 (7.6, 9.7)	8.6 (7.5, 9.7)	9.9 (3.3, 16.6)	
Some other way	8.5 (6.9, 10.1)	8.6 (7.0, 10.3)	4.5 (1.3, 7.8)	
How difficult to get LSD				<0.001 <sup>c</sup>
Probably Impossible	41.0 (40.6, 41.3)	41.2 (40.9, 41.6)	3.2 (2.1, 4.2)	
Very Difficult	23.3 (23.0, 23.6)	23.4 (23.1, 23.7)	12.3 (10.6, 14.0)	
Fairly Difficult	16.8 (16.5, 17.0)	16.6 (16.4, 16.9)	31.4 (29.2, 33.7)	
Fairly Easy	9.3 (9.1, 9.4)	9.1 (8.9, 9.2)	34.3 (31.6, 36.9)	
Very Easy	3.8 (3.7, 3.9)	3.7 (3.6, 3.8)	18.7 (17.0, 20.3)	
Don't Know	5.9 (5.7, 6.0)	5.9 (5.8, 6.1)	0.14 (0.00, 0.32)	
Approached by drug seller / Past Month				<0.001 <sup>c</sup>
Yes	5.6 (5.5, 5.8)	5.4 (5.3, 5.5)	39.5 (37.6, 41.4)	
No	94.4 (94.2, 94.5)	94.6 (94.5, 94.7)	60.5 (58.6, 62.4)	

**Supplemental Table 1. Drug Use Characteristics by Past Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

Survey Question	Overall	LSD Use within the past year		
		No Past Year Use	Past Year Use	p-value
<b>about Drug Use</b>	<b>(N=282,768)</b>	<b>(N=279,136)</b>	<b>(N=3,632)</b>	

Frequencies presented are unweighted counts. Weighted proportions and 95% confidence intervals are reported. \*Imputed or recoded variable reported. P-values: a=linear regression; b=linear regression with log transformation; c=Rao-Scott chi-square test. SAS Survey Procedures used for all analyses.

**Supplemental Table 2. Risk Attitudes by Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

Survey Question	Overall	LSD Use within the past year		
		No Past Year Use	Past Year Use	p-value
<b>Risk Smoking Marijuana Once or Twice A Week</b>	<b>(N=282,768)</b>	<b>(N=279,136)</b>	<b>(N=3,632)</b>	<b>&lt;0.001<sup>c</sup></b>
No Risk	18.9 (18.6, 19.1)	18.5 (18.2, 18.8)	65.9 (63.9, 68.0)	
Slight Risk	24.6 (24.4, 24.9)	24.6 (24.3, 24.9)	26.9 (25.0, 28.7)	
Moderate Risk	23.1 (22.8, 23.4)	23.3 (23.0, 23.5)	5.7 (4.5, 7.0)	
Great Risk	31.8 (31.5, 32.1)	32.0 (31.7, 32.3)	1.4 (0.86, 1.9)	
Don't Know	1.6 (1.5, 1.7)	1.6 (1.5, 1.7)	0.11 (0.00, 0.23)	
<b>Risk Trying LSD Once or Twice</b>	<b>(N=282,768)</b>	<b>(N=279,136)</b>	<b>(N=3,632)</b>	<b>&lt;0.001<sup>c</sup></b>
No Risk	3.5 (3.4, 3.6)	3.2 (3.1, 3.3)	34.9 (32.5, 37.3)	
Slight Risk	10.9 (10.7, 11.1)	10.7 (10.5, 10.9)	43.4 (41.2, 45.6)	
Moderate Risk	16.8 (16.6, 17.0)	16.8 (16.6, 17.0)	14.1 (12.5, 15.7)	
Great Risk	66.3 (66.0, 66.7)	66.8 (66.4, 67.1)	7.4 (6.3, 8.5)	
Don't Know	2.5 (2.4, 2.6)	2.5 (2.4, 2.6)	0.22 (0.00, 0.50)	
<b>Risk Using LSD Once or Twice A Week</b>	<b>(N=282,768)</b>	<b>(N=279,136)</b>	<b>(N=3,632)</b>	<b>&lt;0.001<sup>c</sup></b>

<b>Supplemental Table 2. Risk Attitudes by Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.</b>				
	Overall	LSD Use within the past year		
		No Past Year Use	Past Year Use	
Survey Question	(N=282,768)	(N=279,136)	(N=3,632)	p-value
No Risk	1.5 (1.4, 1.5)	1.4 (1.3, 1.4)	12.0 (10.6, 13.5)	
Slight Risk	3.5 (3.4, 3.7)	3.4 (3.3, 3.5)	23.0 (21.1, 24.9)	
Moderate Risk	12.1 (12.0, 12.3)	12.0 (11.8, 12.2)	32.2 (30.1, 34.2)	
Great Risk	80.4 (80.1, 80.6)	80.7 (80.5, 81.0)	32.6 (30.0, 35.1)	
Don't Know	2.5 (2.4, 2.6)	2.5 (2.4, 2.6)	0.23 (0.02, 0.44)	
Risk Trying Heroin Once or Twice				<b>&lt;0.001<sup>c</sup></b>
No Risk	1.2 (1.1, 1.2)	1.2 (1.1, 1.2)	2.3 (1.5, 3.0)	
Slight Risk	3.6 (3.4, 3.7)	3.5 (3.4, 3.7)	7.1 (5.5, 8.7)	
Moderate Risk	9.3 (9.1, 9.5)	9.3 (9.1, 9.5)	15.1 (13.1, 17.1)	
Great Risk	84.3 (84.0, 84.6)	84.4 (84.1, 84.6)	75.1 (72.4, 77.7)	
Don't Know	1.6 (1.5, 1.7)	1.6 (1.5, 1.7)	0.48 (0.17, 0.79)	
Risk Using Heroin Once or Twice A Week				<b>0.002<sup>c</sup></b>
No Risk	0.91 (0.86, 0.96)	0.91 (0.86, 0.96)	0.83 (0.37, 1.3)	
Slight Risk	0.99 (0.94, 1.05)	0.99 (0.94, 1.05)	1.1 (0.54, 1.7)	
Moderate Risk	3.9 (3.7, 4.0)	3.9 (3.7, 4.0)	4.8 (3.8, 5.8)	
Great Risk	92.7 (92.5, 92.8)	92.7 (92.5, 92.8)	92.8 (91.5, 94.1)	
Don't Know	1.6 (1.5, 1.6)	1.6 (1.5, 1.6)	0.44 (0.15, 0.73)	
Risk Using Cocaine Once or Twice A Week				<b>&lt;0.001<sup>c</sup></b>
No Risk	1.04 (0.99, 1.09)	1.04 (0.99, 1.09)	1.3 (0.79, 1.8)	
Slight Risk	2.6 (2.4, 2.7)	2.5 (2.4, 2.6)	10.8 (9.1, 12.4)	

**Supplemental Table 2. Risk Attitudes by Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

Survey Question	Overall (N=282,768)	LSD Use within the past year		p-value
		No Past Year Use (N=279,136)	Past Year Use (N=3,632)	
Moderate Risk	9.5 (9.3, 9.7)	9.4 (9.2, 9.6)	30.7 (28.1, 33.2)	
Great Risk	85.3 (85.1, 85.6)	85.5 (85.3, 85.8)	57.1 (54.7, 59.5)	
Don't Know	1.6 (1.5, 1.6)	1.6 (1.5, 1.7)	0.17 (0.04, 0.29)	
Risk Having 5 or More Drinks Once or Twice A Week				<b>&lt;0.001<sup>c</sup></b>
No Risk	3.2 (3.1, 3.3)	3.1 (3.0, 3.2)	5.8 (4.6, 7.0)	
Slight Risk	16.6 (16.4, 16.8)	16.5 (16.3, 16.7)	30.7 (28.0, 33.4)	
Moderate Risk	35.1 (34.9, 35.4)	35.1 (34.8, 35.4)	39.0 (36.2, 41.8)	
Great Risk	44.2 (43.9, 44.5)	44.4 (44.1, 44.7)	24.3 (22.3, 26.3)	
Don't Know	0.91 (0.85, 0.96)	0.91 (0.86, 0.97)	0.18 (0.04, 0.33)	
Get A Real Kick Out Of Doing Dangerous Things				<b>&lt;0.001<sup>c</sup></b>
Never	54.3 (53.9, 54.6)	54.6 (54.3, 54.9)	10.5 (9.0, 12.0)	
Seldom	28.2 (27.9, 28.5)	28.2 (27.9, 28.5)	27.8 (25.6, 30.0)	
Sometimes	15.0 (14.8, 15.2)	14.7 (14.5, 14.9)	47.5 (45.4, 49.5)	
Always	2.6 (2.5, 2.7)	2.5 (2.4, 2.6)	14.2 (12.7, 15.6)	
Like To Test Yourself By Doing Risky Things				<b>&lt;0.001<sup>c</sup></b>
Never	53.9 (53.6, 54.2)	54.2 (53.9, 54.5)	13.7 (12.1, 15.2)	
Seldom	32.0 (31.7, 32.3)	32.0 (31.7, 32.3)	37.4 (35.1, 39.7)	
Sometimes	12.5 (12.4, 12.7)	12.3 (12.2, 12.5)	39.8 (37.8, 41.9)	
Always	1.6 (1.5, 1.7)	1.5 (1.5, 1.6)	9.1 (8.0, 10.2)	

**Supplemental Table 2. Risk Attitudes by Past-Year LSD Use from NSDUH Survey Respondents from 2015-2019.**

Survey Question	Overall (N=282,768)	LSD Use within the past year		
		No Past Year Use (N=279,136)	Past Year Use (N=3,632)	p-value
		Frequencies presented are unweighted counts. Weighted proportions and 95% confidence intervals are reported. *Imputed or recoded variable reported. P-values: a=linear regression; b=linear regression with log transformation; c=Rao-Scott chi-square test. SAS Survey Procedures used for all analyses.		

**Supplemental Table 3. Drug Use Characteristics for all Study Respondents by Past-Year LSD Use per Study Year**

	2015	2016	2017	2018	2019	2015 vs 2019	Year x Var
<b>Demographic Characteristics</b>	<b>Statistics</b>	<b>(N=56,897)</b>	<b>(N=56,276)</b>	<b>(N=56,313)</b>	<b>(N=56,136)</b>	<b>p-value</b>	<b>p-value</b>
Past Year LSD Use	15.2 (13.7, 16.7)	18.4 (16.6, 20.2)	21.2 (19.3, 23.0)	22.2 (20.2, 24.2)	23.1 (21.1, 25.1)	<.0001	<.0001
<b>ANY TOBACCO - EVER USED</b>							
No LSD Use	63.6 (62.9, 64.2)	62.7 (62.1, 63.4)	62.4 (61.8, 63.0)	61.2 (60.5, 61.9)	60.8 (60.0, 61.6)	<.0001	0.35
Past Year LSD Use	93.7 (91.5, 95.9)	93.3 (90.6, 96.0)	93.8 (91.6, 96.0)	94.8 (93.0, 96.7)	91.7 (88.8, 94.5)		
<b>ANY TOBACCO - PAST YEAR USE</b>							
No LSD Use	29.1 (28.5, 29.7)	28.2 (27.6, 28.8)	27.0 (26.4, 27.6)	26.3 (25.6, 27.0)	25.9 (25.3, 26.5)	<.0001	0.55
Past Year LSD Use	82.8 (79.4, 86.2)	77.5 (73.1, 81.8)	77.8 (72.8, 82.8)	75.9 (71.3, 80.6)	72.9 (67.5, 78.3)		
<b>ALCOHOL - EVER USED</b>							

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

No LSD Use	80.9 (80.4, 81.4)	80.0 (79.6, 80.5)	80.8 (80.3, 81.3)	80.6 (80.1, 81.1)	80.1 (79.5, 80.7)	0.06	0.77
Past Year LSD Use	98.1 (96.9, 99.3)	98.5 (97.4, 99.7)	98.5 (97.5, 99.5)	98.2 (97.1, 99.3)	98.7 (97.6, 99.8)		
MARIJUANA - EVER USED							
No LSD Use	43.7 (42.8, 44.5)	43.5 (42.8, 44.2)	44.7 (43.9, 45.4)	44.8 (44.0, 45.6)	45.9 (45.2, 46.7)	<b>&lt;.00 01</b>	0.18
Past Year LSD Use	97.1 (95.3, 99.0)	97.7 (95.6, 99.7)	98.8 (97.8, 99.8)	99.0 (98.3, 99.8)	98.3 (97.3, 99.3)		
COCAINE - EVER USED							
No LSD Use	14.3 (13.8, 14.8)	14.1 (13.6, 14.6)	14.5 (14.1, 14.9)	14.3 (13.8, 14.9)	14.6 (14.1, 15.1)	0.25	0.19
Past Year LSD Use	60.3 (55.9, 64.6)	58.0 (53.3, 62.7)	64.1 (59.9, 68.2)	64.0 (59.2, 68.8)	63.8 (59.4, 68.2)		
"CRACK" - EVER USED							
No LSD Use	3.3 (3.0, 3.5)	3.2 (3.0, 3.4)	3.5 (3.2, 3.7)	3.4 (3.2, 3.7)	3.3 (3.1, 3.6)	0.51	0.17
Past Year LSD Use	10.4 (6.9, 13.9)	7.9 (4.9, 10.8)	13.0 (9.5, 16.4)	11.5 (7.3, 15.7)	13.1 (9.9, 16.2)		
HEROIN - EVER USED							
No LSD Use	1.8 (1.6, 2.0)	1.7 (1.6, 1.9)	1.9 (1.7, 2.1)	1.8 (1.7, 2.0)	2.0 (1.8, 2.2)	0.17	0.79
Past Year LSD Use	13.9 (10.1, 17.7)	12.1 (9.0, 15.1)	13.7 (10.1, 17.3)	11.8 (8.7, 14.9)	9.4 (6.4, 12.4)		
PCP - EVER USED							
No LSD Use	2.3 (2.1, 2.5)	2.3 (2.1, 2.5)	2.3 (2.1, 2.5)	2.3 (2.0, 2.5)	2.0 (1.7, 2.2)	<b>0.04</b>	0.37
Past Year LSD Use	8.6 (4.9, 12.4)	7.7 (5.0, 10.3)	5.3 (3.2, 7.5)	4.9 (2.9, 6.9)	6.4 (4.0, 8.8)		

ECSTASY - EVER USED							
No LSD Use	6.6 (6.3, 6.9)	6.3 (6.1, 6.6)	6.6 (6.3, 6.9)	6.9 (6.5, 7.2)	6.7 (6.4, 7.0)	0.11	0.10
Past Year LSD Use	74.3 (69.6, 78.9)	64.3 (59.7, 68.8)	63.3 (57.5, 69.0)	69.2 (65.2, 73.3)	67.8 (63.3, 72.3)		
KETAMINE - EVER USED							
No LSD Use	1.05 (0.94, 1.2)	1.1 (1.00, 1.2)	1.1 (1.01, 1.2)	1.2 (1.01, 1.3)	1.2 (1.04, 1.3)	<b>0.01</b>	0.47
Past Year LSD Use	20.5 (15.2, 25.9)	20.9 (16.4, 25.5)	20.3 (15.5, 25.1)	20.0 (15.9, 24.2)	25.0 (20.0, 29.9)		
INHALANTS - EVER USED							
No LSD Use	9.3 (9.0, 9.7)	8.9 (8.5, 9.2)	9.1 (8.7, 9.5)	8.8 (8.4, 9.2)	8.8 (8.4, 9.2)	0.06	0.08
Past Year LSD Use	41.3 (36.2, 46.4)	36.9 (31.6, 42.2)	38.4 (34.3, 42.5)	45.6 (40.8, 50.4)	40.0 (34.8, 45.2)		
METHAMPHETAMINE - EVER USED							
No LSD Use	5.4 (5.1, 5.7)	5.3 (5.1, 5.5)	5.3 (5.0, 5.7)	5.3 (5.1, 5.6)	5.7 (5.3, 6.1)	0.12	<b>0.04</b>
Past Year LSD Use	14.0 (9.9, 18.2)	19.5 (15.3, 23.7)	22.9 (18.4, 27.5)	20.2 (15.5, 24.9)	22.6 (18.6, 26.6)		
PAIN RELIEVERS - EVER MISUSED							
No LSD Use	10.1 (9.7, 10.4)	9.8 (9.5, 10.2)	9.6 (9.2, 10.0)	9.1 (8.7, 9.5)	9.1 (8.7, 9.4)	<b>0.0002</b>	0.95
Past Year LSD Use	51.1 (45.6, 56.7)	48.9 (42.2, 55.5)	49.6 (45.3, 53.9)	45.5 (40.7, 50.2)	45.2 (40.3, 50.2)		
STIMULANTS - EVER MISUSED							
No LSD Use	3.5 (3.3, 3.7)	3.9 (3.7, 4.2)	3.9 (3.7, 4.1)	3.5 (3.3, 3.7)	3.8 (3.6, 4.0)	<b>0.01</b>	0.87



Past Year LSD Use	49.4 (45.1, 53.8)	47.2 (41.7, 52.8)	47.2 (42.1, 52.3)	45.4 (41.3, 49.5)	45.2 (39.6, 50.7)		
TRANQUILIZERS - EVER MISUSED							
No LSD Use	4.0 (3.8, 4.3)	4.2 (3.9, 4.4)	4.1 (3.8, 4.3)	3.9 (3.6, 4.1)	3.9 (3.6, 4.1)	0.65	0.65
Past Year LSD Use	38.0 (32.6, 43.4)	40.3 (36.3, 44.3)	37.6 (32.3, 42.9)	38.9 (34.6, 43.1)	36.6 (31.2, 42.0)		
SEDATIVES - EVER MISUSED							
No LSD Use	2.1 (1.9, 2.2)	2.3 (2.1, 2.5)	2.3 (2.1, 2.4)	2.0 (1.8, 2.2)	2.1 (1.9, 2.3)	0.68	0.87
Past Year LSD Use	13.7 (10.5, 17.0)	12.9 (9.2, 16.6)	12.8 (9.5, 16.1)	13.4 (9.9, 16.9)	12.1 (8.4, 15.8)		
EVER USED PEYOTE							
No LSD Use	2.0 (1.8, 2.3)	2.1 (1.9, 2.3)	2.0 (1.8, 2.2)	2.2 (2.0, 2.4)	2.0 (1.8, 2.3)	1.00	0.43
Past Year LSD Use	8.4 (5.2, 11.5)	8.4 (5.7, 11.2)	5.1 (2.7, 7.5)	9.3 (6.1, 12.5)	6.3 (3.9, 8.7)		
EVER USED MESCALINE							
No LSD Use	3.0 (2.6, 3.3)	3.0 (2.8, 3.2)	2.7 (2.5, 3.0)	2.7 (2.5, 3.0)	2.7 (2.4, 2.9)	0.19	0.81
Past Year LSD Use	12.5 (9.0, 16.0)	10.5 (6.8, 14.1)	9.5 (6.9, 12.1)	8.7 (4.8, 12.5)	9.7 (6.8, 12.7)		
EVER USED PSILOCYBIN (MUSHROOMS)							
No LSD Use	8.2 (7.8, 8.6)	8.0 (7.6, 8.3)	8.4 (8.0, 8.7)	8.8 (8.4, 9.2)	8.6 (8.1, 9.0)	<b>0.046</b>	0.14
Past Year LSD Use	68.8 (63.9, 73.6)	64.0 (58.3, 69.7)	66.9 (62.2, 71.5)	71.8 (67.1, 76.5)	71.6 (67.8, 75.5)		
HALLUCINOGEN DEPENDENCE OR							

<b>ABUSE - PAST YEAR</b>							
No LSD Use	0.05 (0.04, 0.07)	0.08 (0.06, 0.11)	0.07 (0.04, 0.09)	0.05 (0.03, 0.07)	0.06 (0.04, 0.09)	0.81	0.42
Past Year LSD Use	7.9 (5.1, 10.6)	7.3 (4.7, 10.0)	7.1 (4.7, 9.5)	6.6 (4.8, 8.4)	4.8 (2.9, 6.8)		
<b>EVER USED NEEDLE TO INJECT DRUGS</b>							
No LSD Use	1.6 (1.4, 1.8)	1.6 (1.4, 1.8)	1.6 (1.4, 1.8)	1.6 (1.4, 1.8)	1.7 (1.5, 1.8)	0.67	0.94
Past Year LSD Use	7.3 (4.7, 9.9)	7.9 (5.0, 10.8)	7.2 (4.6, 9.8)	6.7 (4.4, 9.1)	6.7 (4.1, 9.4)		
<b>SOLD ILLEGAL DRUGS</b>							
No LSD Use	1.4 (1.3, 1.5)	1.4 (1.3, 1.6)	1.4 (1.2, 1.5)	1.3 (1.2, 1.5)	1.3 (1.1, 1.4)	0.39	0.99
Past Year LSD Use	25.1 (20.8, 29.5)	24.5 (19.8, 29.1)	23.9 (19.6, 28.2)	22.0 (17.5, 26.4)	21.6 (17.9, 25.4)		
<p>All survey questions on drug use were recoded based on previous survey responses. Frequencies presented are unweighted counts. All weighted frequencies are reported as % (95% CI). All associations with Lifetime LSD Use within each survey year were significant, <math>p &lt; 0.001</math> (Rao-Scott chi-square test). All associations are adjusted for survey year, age groups, gender, race, employment status, marital status, education, religious beliefs, criminal arrest, and county metro area. SAS Survey Procedures used for all analyses.</p>							

### Supplement References

- Ambrose, Christopher A, Benjamin W Cowan, and Robert E Rosenman. 2021. “Geographical Access to Recreational Marijuana.” *Contemporary Economic Policy* 39 (4): 778–807. <https://doi.org/10.1111/coep.12518>.
- Fergusson, David M, Joseph M Boden, and L John Horwood. 2012. “Transition to Parenthood and Substance Use Disorders: Findings from a 30-Year Longitudinal Study.” *Drug and Alcohol Dependence* 125 (3): 295–300. <https://doi.org/10.1016/j.drugalcdep.2012.03.003>.
- Folch, Cinta, Percy Fernández-Dávila, Laia Ferrer, Raúl Soriano, Mercedes Díez, and Jordi Casabona. 2015. “[High prevalence of drug consumption and sexual risk behaviors in men who have sex with men].” *Medicina clinica* 145 (3): 102–7. <https://doi.org/10.1016/j.medcli.2014.04.030>.
- Han, Beth, Carlos Blanco, Emily B Einstein, and Wilson M Compton. 2022. “Mental Health Conditions and Receipt of Mental Health Care by Illicit Lysergic Acid Diethylamide (LSD) Use Status among Young Adults in the United States.” *Addiction (Abingdon, England)*, January. <https://doi.org/10.1111/add.15789>.
- Killion, Brittany, Audrey Hang Hai, Abdulaziz Alsolami, Michael G Vaughn, P Sehun Oh, and Christopher P Salas-Wright. 2021. “LSD Use in the United States: Trends, Correlates, and a Typology of Us.” *Drug and Alcohol Dependence* 223 (June): 108715. <https://doi.org/10.1016/j.drugalcdep.2021.108715>.
- Liechti, Matthias E, Patrick C Dolder, and Yasmin Schmid. 2017. “Alterations of Consciousness and Mystical-Type Experiences after Acute LSD in Humans.” *Psychopharmacology* 234 (9–10): 1499–1510. <https://doi.org/10.1007/s00213-016-4453-0>.
- MacNabb, Kathleen, Sarah Blades, Kara Thompson, Daniel J Dutton, Tong Liu, and Mark Asbridge. 2022. “Alcohol Access and Purchasing Behaviour during COVID-19 Pandemic Restrictions: An Exploration of Sociodemographic, Health and Psychosocial Correlates in Two Canadian Provinces.” *Drug and Alcohol Review* 41 (4): 902–11. <https://doi.org/10.1111/dar.13423>.
- Ozga, Jenny E, Catherine Paquette, Jennifer L Syvertsen, and Robin A Pollini. 2022. “Mobile Phone and Internet Use among People Who Inject Drugs: Implications for Mobile Health Interventions.” *Substance Abuse* 43 (1): 592–97. <https://doi.org/10.1080/08897077.2021.1975871>.
- Ross, S, and M Bogenschutz. 2017. “Hallucinogen-Related Disorders.” In *Kaplan & Sadock’s Comprehensive Textbook of Psychiatry*, edited by BJ Sadock, VA Sadock, and P Ruiz, 10th ed., 1312–27. Philadelphia, PA: Wolters Kluwer.
- Tardelli, Vítor Soares, Thiago Marques Fidalgo, Julian Santaella, and Silvia S Martins. 2019. “Medical Use, Non-Medical Use and Use Disorders of Benzodiazepines and Prescription Opioids in Adults: Differences by Insurance Status.” *Drug and Alcohol Dependence* 204 (November): 107573. <https://doi.org/10.1016/j.drugalcdep.2019.107573>.
- Wu, Li-Tzy, He Zhu, and Udi E Ghitza. 2018. “Multicomorbidity of Chronic Diseases and Substance Use Disorders and Their Association with Hospitalization: Results from Electronic Health Records Data.” *Drug and Alcohol Dependence* 192 (November): 316–23. <https://doi.org/10.1016/j.drugalcdep.2018.08.013>.
- Yockey, Andrew, Keith King, and Rebecca Vidourek. 2019. “‘Go Ask Alice, When She’s 10 Feet Tall’: Psychosocial Correlates to Lifetime LSD Use among a National Sample of Adults.”
- Yockey, R Andrew, Rebecca A Vidourek, and Keith A King. 2020. “Trends in LSD Use among

US Adults: 2015–2018.” *Drug and Alcohol Dependence* 212: 108071.  
<https://doi.org/https://doi.org/10.1016/j.drugalcdep.2020.108071>.